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UNWELCOME GUESTS: METHODS OF PATHOLOGIC ESCAPE 
FROM MHC CLASS I-MEDIATED IMMUNITY 
HARIMANDER KHALSA 
ABSTRACT 
Major histocompatibility complex class I (MHC-I) proteins are responsible for the 
presentation of intracellular protein fragments on the cellular surface and are thus 
the primary method for the broader immune system to recognize and respond to 
intracellular deformity or infection. A successful immune response against 
intracellular pathogens relies upon effective epitope presentation by MHC-I and 
recognition of this epitope by cytotoxic cluster of differentiation 8 positive (CD8+) 
T cells. Although MHC-I mediated immunity is a powerful mechanism which 
might resist infection by pathogens, many such pathogens have evolved 
methods of eluding or suppressing MHC-I mediated immune responses and are 
thereby able to persist within our cells. Close study of the fine details of the 
functionality of the MHC-I mediated antigen presentation system may yield 
important clues about how to best move forward in the quest to eliminate these 
problematic diseases. Although diseases such as tuberculosis, malaria, human 
immunodeficiency virus (HIV), and cancer may differ in many fundamental ways, 
it has become clear that the future of treating these elusive pathogens must 
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The human immune system incorporates a plethora of powerful mechanisms for 
identifying and combating infection. However, only a subset of these 
mechanisms remains effective once a pathogen has taken residence inside a 
human cell. Prominent components of the immune system can no longer play 
their usual role in such cases (Tam & Jacques, 2014). Fortunately, there remains 
a set of mechanisms for the immune system to identify and combat intracellular 
pathogens. One of such mechanisms is major histocompatibility complex class I 
(MHC-I), which is able to present intracellular protein fragments for recognition by 
cytotoxic cluster of differentiation (CD8+) T cells (also known as cytotoxic T 
lymphocytes or CTLs). Nearly every nucleated cell in the human body expresses 
MHC-I complexes on its cellular surface. Cytosolic proteins are regularly digested 
by proteases, and some fragments of these digested proteins are regularly 
translocated by the transporter associated with antigen processing (TAP) 
complex into the endoplasmic reticulum (ER) of the cell, where they may 
associate with nascent MHC-I proteins. Following their binding to protein 
fragments, MHC-I molecules are presented on the cellular surface for recognition 
by CTLs (Garcia‐Lora et al., 2003). Notably, MHC-I complexes possess a peptide 
binding site that is highly variable across the human population but generally 
retains the ability to bind certain characteristic protein fragments. As a result, 
some protein fragments derived from proteins belonging to intracellular 
pathogens will inevitably be presented by MHC-I to CTLs, at which point the 
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CTLs induce apoptosis in the host cell of the pathogen to limit further spread of 
the infection (Rock et al., 2016). 
 
Advances in medicine across the last century have provided treatments for 
managing many deadly and damaging illnesses, but some pathogens still remain 
resistant. Prominent examples of such pathogens which have continuously 
eluded attempts to develop effective and long-lasting treatments include 
herpesviruses, human immunodeficiency virus (HIV), tuberculosis, malaria, and 
cancer. A key factor that these particularly notable examples share is their ability 
to elude, suppress, or escape immune response while residing and functioning 
inside human cells. Although MHC-I mediated immunity is a powerful mechanism 
for resisting infection, many pathogens have evolved methods of eluding or 
suppressing MHC-I mediated immune responses. Beyond the influence of this 
critical defense, pathogens are then able to reside freely within human cells, 
where they are not vulnerable to other important components of the immune 
system including antibodies, the complement system, and macrophages. 
Although MHC-I mediated immunity has proven vulnerable to escape by many of 
these dangerous pathogens, this system still remains the most robust method of 
recognizing and managing intracellular invaders (Rock et al., 2016). Close study 
of the fine details of the functionality of this system may yield important clues 







The MHC (major histocompatibility complex) class I or HLA (human leukocyte 
antigen) class I gene family is a set of genes on human chromosome 6 which 
encodes proteins responsible for the recognition and presentation of short 
peptide fragments roughly 8-11 amino acids in length on the cellular surface for 
recognition by T cells (Falk et al., 1991). There are three classes of MHCs 
present within the human cell, denoted class I, class II, and class III, all of which 
perform different functions. MHC class I proteins are specifically responsible for 
the presentation of intracellular protein fragments on the cellular surface and are 
thus the primary method for the broader immune system to recognize and 
respond to intracellular deformity (cancer) or intracellular pathogens (viruses, 
some bacteria, and parasites). As would be expected given their importance in 
immune function, MHC proteins are expressed throughout most nucleated cells 
in the body, with only a few exceptions including erythrocytes (Brown et al., 
1979). The MHC class I gene family includes three classical genes (HLA-A, HLA-
B, HLA-C), together referred to as class IA genes, and three nonclassical genes 
(HLA-E, HLA-F, HLA-G), referred to as class IB genes. Class IA or classical 
MHC genes are responsible for the function that is primarily associated with MHC 
class I genes: they bind peptides and present them on the cellular surface. The 
sequence of these three classical MHC genes is highly polymorphic, with an 
estimated 8-9 million different alleles within the human population (Robinson et 
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al., 2017). Although all classical MHC proteins retain the same general 
functionality, these polymorphisms result in proteins which will preferentially bind 
and present different peptides. This polymorphism is thought to serve as a 
species-level protection mechanism, ensuring that no one virus or bacterium can 
be capable of consistently eluding MHC-I mediated antigen presentation across 
many different members of the human species (Borghans et al., 2004). As both 
alleles of each gene are expressed, a typical individual will have up to 6 different 
classical MHC proteins, each of which will present a different subset of peptides 
resulting in a diverse snapshot of the cytosolic contents. The function of class IB 
MHC genes is less well defined, although they are known to have an important 
role in inhibiting the activation of natural killer cells and are therefore a subject of 
continuing research (Braud et al., 1998; Lee et al., 1998; Pazmany et al., 1996). 
Interestingly, although these nonclassical MHC proteins are far less polymorphic 
when compared with classical MHC proteins, they are still capable of presenting 
peptides on the cellular surface in the same manner as class IA MHC proteins. 
Instead of having a polymorphic but highly specific peptide binding groove as 
classical MHC proteins do, nonclassical MHC proteins have a wider peptide 
binding groove that can accept a greater variety of peptides, though these 
peptides usually bear some similarity to those most readily bound by classical 





MHC class I receptors are single-pass transmembrane heterodimers which 
include a heavy α chain encoded by an HLA gene (e.g., HLA-A, HLA-B, HLA-C) 
and a light β chain, beta-2-microglobulin, encoded by a separate gene (Figure 1). 
Within the α chain, there are three extracellular domains denoted α1, α2, and α3, 
in addition to a transmembrane domain and a cytosolic tail domain. Of the three 
extracellular domains, α1 and α2 are responsible for peptide binding, and α3 is 
responsible for beta-2-microglobulin binding and stabilization of the interaction 
with T-cell receptor (TCR) proteins. Specifically, there is a peptide binding groove 
between the α1 and α2 subunits into which peptides can be bound (Bjorkman et 






Figure 1. Structure of the MHC class 1 protein HLA-A2. This figure shows the 
four domains (α1, α2, α3, and β2m) of HLA-A2. β2m = Beta-2-Microglobulin; HLA 






The heavy α chain first folds within the smooth endoplasmic reticulum (ER) with 
the assistance of calnexin and calreticulin (Figure 2). Once the α chain is fully 
folded, it joins the peptide loading complex (PLC) alongside the transporter 
associated with antigen processing (TAP) (Sadasivan et al., 1996). TAP is a 
heterodimeric ATP-binding cassette (ABC) transporter protein which consists of 
the TAP1 and TAP2 subunits and is integrated within the ER membrane. It is 
responsible for the import of peptide fragments produced by cytosolic proteases 
into the endoplasmic reticulum for loading onto MHC (Koch et al., 2004). As 
peptides enter the ER, they may be trimmed by ER aminopeptidases (ERAPs), 
an action that leads to a greater proportion of peptides of the appropriate 8-11 
amino acid length for MHC binding (Chang et al., 2005). Because the assembled 
MHC protein is unstable and will dissociate in the absence of bound peptide, the 
PLC, which includes a chaperone protein called tapasin, helps to stabilize the 
complex while peptide binding occurs. Once the MHC protein is able to bind a 
suitable peptide and form a stable complex, it begins the process of vesicular 


























Figure 2. The MHC-I assembly, peptide loading, and presentation process. 
This figure diagrams the entire step-by-step process of MHC synthesis and 
assembly. First, the MHC class I and beta-2-microglobulin genes are transcribed 
from DNA in the nucleus, and the transcripts are co-translationally transported to 
the ER. From there, folding and assembly of the protein complex is facilitated by 
calnexin, calreticulin, and tapasin. Then, cytosolic peptides produced by the 
proteasome are transported into the ER by TAP and are loaded into the complex. 
The mature HLA complex is then glycosylated and transported through the Golgi 
complex to the cellular surface. ER =Endoplasmic Reticulum; HLA = Human 
Leukocyte Antigen; MHC = Major Histocompatibility Complex; RNA = Ribonucleic 
Acid; mRNA = Messenger RNA; TAP = Transporter Associated with Antigen 
Processing. Adapted from (Garcia‐Lora et al., 2003). 
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TAP-INDEPENDENT PROCESSING PATHWAYS 
Research has yielded clues that MHC-I can still be loaded with cytosolic proteins 
and maintain some of its functionality in the absence of functional TAP protein 
(de la Salle et al., 2002; Lorente et al., 2019; Neumeister et al., 2001). Although it 
is currently unclear how this mechanism functions, there are several theories that 
highlight ATP-binding cassette (ABC) transporter proteins which share structural 
and functional similarities with TAP (Nöll et al., 2017; Wolters et al., 2005). Some 
other research indicates that peptides loaded into MHC-I independently of TAP 
can be derived from proteins which enter the ER as a part of the membrane 
trafficking process (Oliveira et al., 2013). There are yet other TAP-independent 
processing pathways that have been shown to be capable of delivering 
endocytosed extracellular antigens for presentation by means of MHC-I 
(Bachmann et al., 1995; Voeten et al., 2001). This pathway for presenting 
exogenous peptides is specific to a subset of cells known as antigen-presenting 
cells (APCs) (Rock et al., 1993). In general, it is clear that these alternative 
peptide processing pathways are generally less efficient and produce a different 
profile of proteins for presentation by means of MHC than traditional TAP-
dependent pathways (Zhou et al., 1993). This is not to say, however, that TAP-
independent processing pathways are not capable of facilitating an effective 
MHC-mediated immune response, as this capability has been demonstrated (de 





Once a mature MHC protein presents its bound peptide on the cellular surface, 
the peptide can be recognized by mature CTLs. If a CTL recognizes the 
presented peptide as a non-self antigen, the CTL can then facilitate destruction 
of the cell which presented it (Alberts et al., 2015). Through this method, the 
immune system can eliminate cells that are mutated or infected with viruses or 
other intracellular pathogens and thereby effectively fight these diseases (Irvine 
et al., 2002). 
 
CROSS-PRESENTATION & ANTIGEN-PRESENTING CELLS (APCs) 
Before naive CTLs can become active effector CTLs, they must first interact with 
antigen-presenting cells (APCs) in a process called cross-presentation (Sei et al., 
2015). This process is essential in priming the immune system to recognize 
invaders such as viruses, bacteria, or cancerous cells and to initiate an immune 
response specific to these invaders (Irvine et al., 2002). Antigen-presenting cells 
are a group of cell types that include macrophages, dendritic cells, and others. 
These cells perform an important function of endocytosing or phagocytosing 
foreign proteins or organisms within the body, breaking them down, and then 
presenting the derived antigens to the broader immune system. In cross-
presentation, APCs present antigens derived from either foreign or self-derived 
proteins through their MHC-I antigen presentation pathway to the CTLs (Figure 
3). When an antigen is presented to a CTL by an APC and the CTL is able to 
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bind the MHC-antigen complex using its T-cell receptor (TCR), the APC then 
activates the CTL, which can then target cells that present the same antigen for 
destruction (Rock et al., 1993). Cross-presentation is also a mechanism through 
which the immune system can develop tolerance for self-antigens. The selection 
of CTLs for self-antigen tolerance occurs primarily in the thymus and is known as 
thymic selection. During thymic selection, only CTLs that do not strongly bind 
self-antigens are allowed to proceed, a process known as negative selection 
(Jameson et al., 1994). Another important result of this process is that CTLs are 
selected to be MHC-restricted, which means they are selected to specifically bind 
peptides bound to the MHC proteins found within the body (Gomard et al., 1986). 
Thus, CTLs are actually selected to bind specific MHC-peptide pairs and not just 
MHC proteins or peptides alone. 
 
MHC CLASS II  
MHC class II proteins share many similarities in structure and function with MHC 
class I proteins (Brown et al., 1993). Whereas MHC class I proteins are 
expressed throughout the body, MHC class II proteins are expressed exclusively 
by antigen-presenting cells (APCs). Another difference between the MHC-I 
antigen presentation pathway and the MHC-II antigen presentation pathway is 
that antigens presented by MHC-II are recognized by CD4+ T cells, also known 
as T-helper cells, instead of CTLs. Unlike CTLs, T-helper cells do not act directly 
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to eliminate infected cells but rather act to stimulate a broader immune response 
through releasing immunostimulatory cytokines (Ridge et al., 1998). 
Figure 3. Cross-presentation of viral antigens by a dendritic cell. This 
diagram shows a dendritic cell (purple) cross-presenting viral antigens to a naive 
CTL, causing it to mature and target a virally infected cell by means of TCR-MHC 
binding. A T-helper cell (red) is activated by dendritic cell presentation of viral 
antigens through the MHC-II antigen presentation pathway. CD = Cluster of 
Differentiation; CTL = Cytotoxic T Lymphocyte; MHC =Major Histocompatibility 
Complex; TCR = T-Cell Receptor. Adapted from (Rosendahl Huber et al., 2014).  
 
NATURAL KILLER CELLS 
As humans have continued to co-evolve with many of the viruses, bacteria, and 
parasites that cause infection, these pathogens have developed various methods 
for disabling or downregulating the MHC class I antigen presentation pathway 
(Alberts et al., 2015). Without a functional antigen presentation pathway, the 
immune system becomes blinded to intracellular processes and is therefore 
unable to eliminate infected cells. To handle this issue, another type of immune 
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cell known as a natural killer (NK) cell binds MHC proteins which present 
peptides on the cellular surface. However, instead of destroying cells that present 
non-self peptides, NK cells act to destroy cells that fail to express an adequate 
number of MHC proteins on the cell surface. As these NK cells destroy non-
MHC-presenting cells, they also stimulate an inflammatory response that helps to 
recruit other immune cells to the site of what is likely an infection (Alberts et al., 
2015). MHC downregulation in cells has also been shown to stimulate tolerance 
in NK cells, placing them in a docile state in which they no longer perform their 
primary function, though it is unclear what variables determine the outcome of 
the interaction (Bern et al., 2019). As an example of the power of NK cells, 
researchers transplanted beta-2-microglobulin knockout cancer cells which were 
unable to express MHC protein into immunocompetent rodent hosts, and the 
cancer cells were unable to proliferate unless the population of NK cells in the 
rodent host was first depleted (Das et al., 2017). 
 
IMMUNODOMINANCE  
In response to MHC-I presented peptides, CTLs tend to respond primarily to one 
or several epitopes more than others, and these epitopes are known as the 
immunodominant epitopes. Unfortunately, this tendency offers a mechanism of 
escape to pathogens. If expression of this immunodominant epitope can be 
reduced, the immune system may be less able to respond adequately to other 




WHY DO WE NEED MHC? WHAT HAPPENS WHEN IT DOESN’T WORK? 
MHC class I-mediated antigen presentation is a critical part of the immune 
system that offers an ability to target intracellular pathogens. Many of the most 
difficult to treat diseases share a common ability to elude this mechanism, and 
those that cannot escape it are often more easily handled by the immune system. 
The best evidence for the importance of MHC class I-mediated antigen 
presentation comes from patients in which this system is nonfunctional. To 
demonstrate the importance of a functional MHC class I-mediated antigen 
presentation system, researchers injected mouse hepatitis virus into the brains of 
mice, and approximately 500 times less virus was necessary to constitute a lethal 
dose for mice with a knockout of the beta-2-microglobulin gene (necessary for 
MHC-I complex formation) compared with control mice (Lavi et al., 1999). The 
most common genetic mutation which has been observed clinically that results in 
decreased MHC class I surface presentation is a defect in the TAP gene 
(Matamoros et al., 2001). Without a functional TAP gene, peptide import into the 
ER for MHC complex loading is inhibited, and MHC-peptide complexes are 
unable to form for presentation on the cellular surface. These patients present 
with recurrent and severe infections, including stereotypical necrotizing lesions of 
the skin and respiratory system. However, these infections seem to be primarily 
bacterial in origin and not viral. It is possible that viral immunity is maintained 
through presentation of peptides delivered to the ER through TAP-independent 
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processing pathways (de la Salle et al., 2002). Meanwhile, it is speculated that 
the skin lesions may be related to the destruction of skin cells by NK cells as a 
result of inadequate MHC presentation (de la Salle et al., 1999; Matamoros et al., 
2001). A case study of two siblings with a defective beta-2-microglobulin gene 
and therefore lack of MHC I presentation noted a similar clinical presentation 
(Ardeniz et al., 2015). Even among individuals with a functional MHC antigen 
presentation system, MHC can be an important determining factor in the relative 
ability to resist infection or disease. Many studies have explored the connection 
between MHC genotype and clinical outcomes, and the possession of certain 
MHC alleles can be associated with significantly increased risk of developing 
cancer (Ferreiro-Iglesias et al., 2018).  
 
Given that MHC-mediated antigen presentation serves as one of the primary 
methods by which the immune system recognizes other cells in the body as self, 
it is also involved in autoimmune processes such as Graves’ disease. Graves’ 
disease is an autoimmune disorder in which the immune system recognizes the 
thyroid-stimulating hormone (TSH) receptor protein as non-self, and this 
recognition results in the elicitation of an immune response against thyroid tissue. 
Certain variations in MHC genes have been shown to be a significant risk factor 
for developing Graves’ disease (Bernecker et al., 2013; Chu et al., 2011). 
Similarly, the MHC-CTL interaction is among the most significant obstacles to 
consider when performing organ transplants. Organ recipients typically must be 
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placed on immunosuppressants to prevent the immune system from rejecting 
and destroying a transplanted organ after it is recognized as non-self. In 
transplant donor selection, the MHC alleles carried by both potential donors and 
the recipient are checked to evaluate whether they share common alleles. A 
better transplant donor will carry more of the same MHC alleles because this 
would make it less likely for the recipient’s immune system to recognize the 
transplant tissue as non-self (Flomenberg et al., 2004). To resolve this problem, 
researchers attempted in a recent study to knock out the beta-2-microglobulin 
gene in pig embryos to see if pigs not producing functional MHC-I complexes 
could be raised as potential organ donors (Sake et al., 2019). Although this 
technique remains far from practical use, it demonstrates the importance of MHC 
proteins in the organ transplant process and suggests a potential future for trans-
species organ transplantation as the understanding and control of the MHC 






The specific aims of this study are: 
1. To evaluate mechanisms by which various pathogens are able to bypass, 
disable, or otherwise elude MHC-I mediated immunity. 
2. To review current research regarding ways to restore MHC-I mediated 
immunity and thereby enable an effective immune response to pathogens. 
3. To discuss future research and directions for designing new vaccines and 





MECHANISMS OF ESCAPE FROM MHC-I MEDIATED IMMUNITY 
Throughout the prolonged evolutionary warfare between the immune system and 
various diseases, pathogens have been selected to offer as little visibility to the 
immune system as possible. In the case of intracellular pathogens, this means 
inhibiting the ability of MHC class I proteins to present epitopes derived from 
pathogen proteins. To accomplish this, some pathogens have evolved genes, 
known as immunoevasins, which directly interfere with the functionality of the 
MHC class I-mediated antigen presentation system. In addition, pathogens have 
developed mutations in their most highly immunogenic proteins over time, or they 
have limited expression of such proteins. This section of the study reviews some 
of the mechanisms which allow various diseases to escape the influence of the 
MHC class I-mediated antigen presentation system. 
 
CANCER 
Cancer cells have been shown to escape recognition of their highly mutated 
proteins by the immune system through a number of mechanisms involving 
suppression or deletion of MHC-I complex-related genes (Lei et al., 2018). 
Suppression of MHC-I expression usually takes place through hypermethylation 
of relevant genes, and deletion usually involves either one of the MHC genes or 
the gene encoding beta-2-microglobulin (Cabrera et al., 1996, 2000; Feenstra et 
al., 1999). Despite common reduction in MHC-I mediated antigen presentation 
among tumor cells, NK cells seem to infiltrate tumor tissue very poorly and can 
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be found in fewer numbers in tumor tissue than in surrounding normal tissue, 
even when the tumor tissue is MHC deficient (Del Mar Valenzuela-Membrives et 
al., 2016; Perea et al., 2017). The mechanism by which MHC negative tumor 
cells are able to suppress NK cell activity in this way is still poorly understood.  
 
HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
A hallmark of a virus that is able to effectively manipulate or evade the immune 
system is its ability to persist in the host over a long period of time. Part of the 
reason that human immunodeficiency virus (HIV) is able to overcome the 
immune system so effectively lies in the ability of HIV to rapidly mutate and 
become unrecognizable to antibodies and CTLs in a process known as antigenic 
drift. The restriction of CTLs to HIV epitopes places HIV under selective pressure 
to develop mutations within these epitopes, and HIV will generally develop 
multiple escape mutations throughout the course of infection of a human host 
(Leslie et al., 2004). This process of antigenic drift is not unique to HIV, and other 
viruses are also capable of antigenic drift to varying degrees. Influenza virus is 
well known for its ability to undergo drastic antigenic drift over time, and it is this 
property of the virus that makes vaccine development difficult: no single vaccine 





With its high degree of antigenic drift, HIV has evolved methods to obfuscate 
many of its most prominent antigens. One interesting example of such a method 
is the inclusion of a protein sequence that functions as a proteolytic cleavage site 
within a part of one of its proteins that would otherwise serve as an effective 
epitope for recognition by the host immune system. The presence of this 
cleavage site within the epitope ensures that the epitope will not remain intact 
following proteasomal digestion and thus cannot be bound and presented as a 
whole by means of the MHC-I antigen presentation pathway (Frey et al., 2018). 
Meanwhile, HIV also produces an immunoevasin protein called Nef which 
downregulates MHC-I expression by likely redirecting MHC proteins to 
lysosomes where they are degraded (Liu et al., 2019; Tavares et al., 2020). 
However, given that globally downregulating MHC expression would leave HIV 
more vulnerable to action by NK cells, HIV stimulates expression of nonclassical 
MHC-E protein which inhibits NK cell activity (Nattermann et al., 2005). 
 
EPSTEIN-BARR VIRUS (EBV) 
Epstein-Barr virus (EBV) is a member of the herpesvirus family and one of the 
most prevalent viruses among the human population. In a recent study of 3546 
children, over 50% were found to be seropositive for EBV at the age of 6 (van 
Meel et al., 2020). Unlike some other herpesviruses, Epstein-Barr virus infects B-
cells and can be associated with the development of chronic lymphocytic 
leukemia (Liang et al., 2016). The Epstein-Barr virus genome encodes 
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immunoevasins which help protect the virus from eradication by the host immune 
system and allow the virus to persist throughout the lifespan of the host. Among 
these immunoevasins are the proteins BNLF2a which is a TAP inhibitor, BILF1 
and BDLF3 which degrade MHC-I complexes before they reach the cell surface, 
and BGLF5 which reduces MHC-I expression. In addition to proteins, Epstein-
Barr virus also encodes microRNAs (miRNAs) which interfere with regular 
antigen processing and presentation pathways. Specifically, these miRNAs 
directly block translation of TAP2 messenger RNA (mRNA), reduce expression of 
IL-12 protein by infected B-cells, and decrease expression of EBNA1 protein, an 
important antigen of Epstein-Barr virus recognized by CTLs, by the virus itself 
(Albanese et al., 2016). There is also some evidence to suggest that EBV 
miRNAs may interfere with other cellular functions and that one particular EBV 
miRNA, known as BHRF1-1, may play a direct role in the development of chronic 
lymphocytic leukemia by downregulating tumor suppressor p53 expression (Xu et 
al., 2019).  
 
HERPES SIMPLEX VIRUS (HSV) 
Herpes simplex virus (HSV), another member of the herpesvirus family, 
expresses the protein ICP47 which blocks conformational change in the TAP 
complex and thereby prevents herpesvirus protein fragments from reaching 
newly synthesized MHC-I proteins within the ER (Oldham et al., 2016). TAP 
inhibition has a side effect of dramatically reducing the expression of MHC 
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proteins on the cell surface because MHC proteins are unstable without bound 
peptide. Thus, although HSV is able to elude recognition by CTLs, it can leave 
itself vulnerable to NK cell-mediated immunity (Huard & Früh, 2000; Mégret et 
al., 2007). To counteract this, HSV expresses a protein called US3 which 
interferes with apoptotic signaling and prevents NK cell- or CTL-mediated 
induction of apoptosis in the host cell (Wang et al., 2011). 
 
CYTOMEGALOVIRUS (CMV) 
Cytomegalovirus (CMV) is a member of the herpesvirus family hosted by a large 
portion of the human population. In one study of more than 10,000 American 
subjects, greater than 65% were found to be seropositive for cytomegalovirus 
(Feinstein et al., 2016). Although the virus does not generally result in 
symptomatic infection, it can become active in immunosuppressed patients. As a 
result of long-term coevolution with the human immune system, CMV has 
evolved a number of complex ways of evading or inhibiting MHC-mediated 
immune surveillance. Specifically, it encodes a number of genes referred to as 
immunoevasins, each of which interferes with a component of MHC synthesis, 
assembly, transport, or function. Examples of some of these immunoevasins and 




Table 1. Examples of Cytomegalovirus Immunoevasins and Their Functions 
in Human Host Cellsa 
 
Immunoevasin Function 
US2 & US11 
These immunoevasins facilitate proteasomal 
degradation of MHC through transport from the 
ER into the cytosol (Wiertz, Jones, et al., 1996; 
Wiertz, Tortorella, et al., 1996). 
US3 
This immunoevasin prevents export of MHC 
proteins from the ER to the cellular surface and 
therefore prevents MHC presentation (Jones et 
al., 1996). 
US6 
This immunoevasin inhibits the transport of 
peptides by TAP into the ER for loading into 
MHC (Ahn et al., 1997).  
UL40 
This immunoevasin is loaded onto HLA-E in a 
TAP-independent manner, facilitating the 
stabilization and expression of HLA-E on the cell 
surface (Prod’homme et al., 2012). 
UL18 
This immunoevasin is similar to the MHC class I 
protein HLA-A2 in both sequence and structure 
(Figure 4). It is able to form a full complex with 
beta-2-microglobulin and is capable of binding 
and presenting peptides. This protein binds to 
the NK cell receptor LIR-1 with very high affinity, 
inhibiting NK cell activity while failing to bind to 
other receptors which can lead to immune 
system activation such as TCRs (Chapman et 
al., 1999).  
UL37x1/UL36 
These immunoevasins inhibit CTL-mediated 
lysis of host cells through antiapoptotic 
signaling. With this mechanism in place, even 
CTLs that are able to recognize CMV antigens 
presented by host cell MHC are unable to 
perform their function (Proff et al., 2016). 
 
aThis table lists a number of cytomegalovirus immunoevasin proteins and how they 
function within human host cells to defeat MHC class I-mediated immunity. CMV = 
Cytomegalovirus; CTL = Cytotoxic T Lymphocyte; ER = Endoplasmic Reticulum; HLA = 
Human Leukocyte Antigen; MHC = Major Histocompatibility Complex; NK = Natural 






















Figure 4. Structure of the CMV immunoevasin protein UL18 compared with 
the structures of HLA-A2 and HLA-G proteins. (A) Structure of CMV 
immunoevasin protein UL18 complexed with beta-2-microglobulin (β2m) and 
interacting with LIR-1, a NK cell inhibitory receptor. Structures of human (B) HLA-
A2 and (C) HLA-G proteins complexed with beta-2-microglobulin (β2m) and 
interacting with LIR-1 and LIR-2 NK cell inhibitory receptors, respectively. CMV = 
Cytomegalovirus; HLA = Human Leukocyte Antigen; NK = Natural Killer. Adapted 
from (Yang & Bjorkman, 2008). 
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In addition to interfering with TAP and the MHC antigen presentation system, 
CMV has been shown to have modulatory effects on CTLs themselves. 
Specifically, it has been found that RhCMV, a close relative of human CMV that 
infects rhesus macaques, has the ability to alter the epitope recognition patterns 
of CTLs, directing them to respond to unconventional epitopes. By manipulating 
CTL epitope recognition in this way, RhCMV is able to prevent CTLs from 
responding to conventional RhCMV epitopes and is therefore able to avoid 
targeting of these epitopes by CTLs (Hansen et al., 2013). 
 
TUBERCULOSIS 
Mycobacterium tuberculosis is a dangerous bacterium that evades the host 
immune system through a unique mechanism. It allows itself to be ingested by 
host macrophages and then resides inside macrophage vacuoles. Once bacteria 
are ingested by a macrophage, they are usually destroyed as a result of a 
lysosome containing destructive enzymes and chemicals fusing with the vacuole. 
M. tuberculosis has a mechanism for preventing the fusion of these lysosomes 
with vacuoles, can interfere with some of the host macrophage cellular functions 
through methyltransferases and other methods, and is generally very resistant to 
breakdown by lysosomal enzymes and reactive oxygen species (Pethe et al., 
2004; Voskuil et al., 2011). With lysosomal fusion and several other cellular 
mechanisms defeated, M. tuberculosis is free to reside within macrophage 
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vacuoles, beyond the purview of the immune system or even the MHC-I pathway 
of the macrophage itself.  
 
As yet another layer of protection from the immune system, M. tuberculosis 
expresses a protein called PPE38 which downregulates MHC-I expression and 
interferes with the CTL priming process (Meng et al., 2017). Similar to other 
pathogens that downregulate MHC-I expression, M. tuberculosis seems capable 
of inhibiting NK cell function as well. Although the exact mechanism is unclear, 
the T-cell immunoglobulin and mucin domain-3 (Tim-3) pathway has been 
implicated in this process (Wang et al., 2015). Given that MHC-E plays a 
significant role in CTL response to M. tuberculosis, it is possible that M. 
tuberculosis may upregulate MHC-E as a method to inhibit NK cells (Bian et al., 
2017).  
 
Through these mechanisms, M. tuberculosis can establish lifelong persistent 
infection that is generally resistant to eradication by the powerful adaptive 
mechanisms of the immune system and by vaccines. The Bacillus Calmette-
Guérin (BCG) vaccine, which has long been considered the gold standard of 
vaccines for M. tuberculosis, varies widely in its efficacy, providing protection 
from infection in only 15% or less of the cases in some regions (Trunz et al., 
2006). Fortunately, antibiotics can be used to good effect against M. tuberculosis; 
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however, multidrug-resistant strains of M. tuberculosis have emerged 
(Toungoussova et al., 2002). 
 
MALARIA  
Malaria, a disease caused by single-celled eukaryotic parasites of the 
Plasmodium genus, is a deadly disease of which there were approximately 228 
million cases worldwide in 2019 (World Health Organization, 2019). Malaria has 
so far defeated all attempts to produce a safe, effective, and mass-producible 
vaccine against it. For example, a recent large-scale clinical trial for a newly 
developed malaria vaccine revealed that the vaccine was only able to prevent 
approximately 30% of malaria infections (RTS,S Clinical Trials Partnership, 
2015). Part of the difficulty in targeting malaria is related to the complexity of the 
life cycle of Plasmodium parasites and the diversity in the antigens which they 
display. Thus, a vaccine against one part of the life cycle of a Plasmodium 
parasite may be ineffective against parasites in another life cycle stage.  
 
As shown in Figure 5, the life cycle of a Plasmodium parasite first begins in an 
insect host such as a mosquito. As the parasite matures into a sporozoite, it is 
delivered to a human host when the mosquito feeds. Upon delivery to a human 
host, the sporozoites enter liver hepatocytes to reproduce asexually into 
merozoites. After completion of this reproductive cycle within hepatocytes, the 
merozoites leave the hepatocyte and enter circulating erythrocytes. Within the 
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erythrocytes, the merozoites enter a cycle of continuous asexual reproduction 
that results in the lysis of the host erythrocyte and the release of the merozoites 
to infect more circulating erythrocytes. This cycle of reproduction within 
erythrocytes continues indefinitely within the human host, with some merozoites 
giving rise to gametocyte offspring which can infect mosquitos that feed on the 
human host. These gametocytes reproduce sexually within the mosquito or other 
insect host to continue the cycle of infection of other hosts (Amino et al., 2006).  
Figure 5. The life cycle of Plasmodium falciparum. This figure shows the 
different stages in the life cycle of Plasmodium falciparum as it develops within 





As a whole, the life cycle of the parasite is finely tuned to limit exposure to the 
immune system. The liver by nature lends itself to immunotolerance, which 
makes it an excellent refuge in which developing parasites can elude immune 
surveillance (Cantor & Dumont, 1967). While residing within hepatocytes, the 
parasites insulate themselves further by encapsulation within a parasitophorous 
vacuolar membrane (PVM), formed through an invagination of the hepatocyte 
cellular membrane in an endocytotic manner. As a result, the parasitic proteins 
are largely insulated from the cytosol where proteins are degraded to produce 
peptides for presentation by means of MHC-I (Suss-Toby et al., 1996). 
 
Research has shown that with adequate priming of CTLs to malaria antigens, it is 
possible for the immune system to destroy the infection at this stage. This result 
indicates that the lack of adequate cross-presentation of malaria antigens is a 
key limiting factor in the elicitation of an adequate immune response. 
Accordingly, by the delivery of a vaccine with live-attenuated sporozoites to mice, 
researchers were able to elicit a more effective immune response. The 
importance of effector CTL function in this response was highlighted by the fact 
that the vaccine lost its effectiveness in beta-2-microglobulin knockout mice 
(White et al., 1996). Meanwhile, merozoites leverage their own immune escape 
by inhabiting erythrocytes, one of very few cells in the body which expresses little 




METHODS OF OVERCOMING IMMUNE ESCAPE 
Despite the various methods of immune escape employed by pathogens, there 
may still remain at least some presentation of pathogen-derived peptides through 
MHC on infected cells. However, the number of remaining MHC proteins 
presenting immunogenic peptides may not be enough to stimulate an adequate 
immune response to the pathogen. Thus, one important goal in treating these 
diseases must lie in priming the immune system to become more sensitive to 
these intermittently presented epitopes. 
 
IMMUNOTHERAPIES 
The human MHC-I mediated antigen presentation often falls short when it comes 
to combating certain diseases such as cancer, resulting in an inability of the 
immune system to effectively target infected cells. In the past, most research 
directly focused on treating disease rather than supporting the innate immune 
function. In pursuit of a more effective way to treat cancer, researchers have 
begun to develop immunotherapies which amplify, modulate, or utilize 
components of the immune system. Although immunotherapy is still a relatively 
new treatment methodology, it has shown great promise in its ability to effectively 
combat cancer.  
 
After many years of studying cancer cells, researchers have recognized a 
number of cell surface antigens specific to certain types of cancer cells, including 
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human epidermal growth factor receptor 2 (HER2) and epidermal growth factor 
receptor (EGFR) (Dong et al., 2019; King et al., 1985; Slamon et al., 2001). 
Although these antigens serve as an easy target for treatments, the immune 
system can sometimes be incapable of effectively targeting them. Early attempts 
to overcome this barrier utilized antigen-specific monoclonal antibodies in 
conjunction with certain adjuvants to help direct the immune system in destroying 
these cancerous cells. Although helpful, these passive antibody-mediated 
immunotherapies are oftentimes only capable of extending patient survival by a 
few months (Le et al., 2013). 
 
Given the shortcomings of antibody-mediated immunotherapies, researchers 
explored strategies to more directly manipulate the immune response to cancer. 
Before T cells can mount an effective response against cancer cells, they must 
first be able to recognize cancer cells as foreign bodies. Solid tumors, especially 
those with limited vascularity, offer very little surface area for recognition by the 
immune system, and in these cases an insufficient number of T cells may 
become adequately primed by APCs to perform their targeted cytotoxic functions. 
Adoptive cell therapy (ACT) is a treatment method in which specific cells are 
isolated from either a patient or a donor, manipulated in vitro, and then infused 




One method of ACT involves isolating T cells directly from a sample of excised 
tumor tissue. These T cells, known as tumor-infiltrating lymphocytes (TILs), are 
selected because they are most likely restricted to tumor-specific antigens. The 
TILs are then treated with immunostimulatory cytokines to stimulate their growth 
in the presence of tumor tissue while they destroy it. Once the tumor tissue is 
destroyed and the population of TILs has grown to a sufficient size, the TILs are 
infused back into the patient to effectively target remaining cancer cells. The idea 
behind this treatment is to essentially isolate the T cells that are most efficient in 
targeting cancer cells and to increase their population so that there are enough of 
them to make a significant difference (Forget et al., 2018).  
 
Some other forms of ACT involve genetic modification of isolated cells. 
Researchers have modified T cells to express CARs (chimeric antigen 
receptors), which are TCRs (T-cell receptors) that are fused with an antibody 
specific to a tumor antigen. As the antibody region of the CAR targets the T cells 
precisely to cancer cell surface antigens, the entire MHC-I mediated antigen 
presentation system can be bypassed, and full manual control can be assumed 
over T-cell targeting. CAR T-cell immunotherapies have been revolutionary in 
their effectiveness compared with many other anticancer therapies and have 
delivered lasting remission from certain cancers (Eshhar et al., 1993; Maude et 




Another newer method of ACT utilizes APCs, specifically dendritic cells (DCs), 
instead of CTLs. As in other forms of ACT, dendritic cells are isolated from a 
patient and then cultured ex vivo. The dendritic cells are treated repeatedly with 
antigenic proteins derived from cancerous cells, which they endocytose and 
begin to cross-present through their MHC-I antigen presentation pathway. The 
dendritic cells are then infused back into the patient where they continue to 
cross-present these antigens, resulting in the MHC restriction of CTLs to 
specifically chosen cancer epitopes. This type of treatment has also been 
effective against HIV infection (Lu et al., 2004). 
 
PEPTIDE-BASED VACCINES 
A promising new direction in treating cancer and some viruses involves peptide-
based vaccines. In this form of therapy, patients are treated with a peptide 
derived from a protein of the target pathogen that is known to be highly 
immunogenic and compatible with presentation by means of MHC. This peptide 
can be delivered to the patient either directly or in the form of a gene through a 
viral vector. Delivery of this peptide to the patient primes the patient’s immune 
system through cross-presentation by DCs to target this foreign peptide 
sequence and can result in better targeting of T cells to infected cells. This type 
of treatment has many advantages, including very low toxicity, high specificity, 
flexibility, and low cost. Unfortunately, research has demonstrated that a peptide 
vaccine administered alone is often insufficient to promote long-lasting remission 
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from cancer (Noguchi et al., 2016; Obara et al., 2017). This may be due to the 
short half-life of peptides in vivo, poor immunogenicity of the peptides 
themselves, or immune escape by the target pathogens. 
 
First-generation peptide vaccines, containing peptides of short length that were 
generally designed to fit MHC-I exactly, yielded limited success. Given the poor 
success with these designs, researchers began to create longer recombinant 
peptides that include multiple epitopes. These longer peptides confer several 
advantages over their shorter cousins. First, these longer peptides are adequate 
in length for presentation by MHC-II proteins which enables activation to T-helper 
cells. When digested by proteases, these longer peptides were still suitable for 
presentation by means of MHC-I, but the extra step involved made these 
peptides less likely to be presented by APCs distant from the site of vaccination, 
a process which has the potential for inducing immune tolerance of the peptides. 
In addition, these longer peptides were able to maintain a longer half-life in vivo. 
When administered with adjuvant APC stimulatory agents, these new 
recombinant peptides resulted in more robust immune responses (Bijker et al., 
2008; Zwaveling et al., 2002). 
 
More recent attempts at synthesizing effective peptide-based vaccines have also 
aimed to target the peptides directly to APCs through numerous means, including 
antibodies, to increase the efficiency of cross-presentation. When administered 
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alongside specific adjuvants, this method can yield powerful effects and could 
notably be used to promote immunotolerance of certain peptides as well. This 
could be a promising direction for research in treating autoimmune disorders or 
transplant rejection (Tacken et al., 2011). 
 
Studies continue to explore the potential of peptide-based vaccines in treating or 
preventing various diseases. In one study, a Plasmodium berghei peptide, which 
was predicted to be highly immunogenic, was delivered directly to mice in the 
form of a gene using a viral vector to be subsequently presented by MHC-I. This 
resulted in the elicitation of a more effective immune response against liver-stage 
sporozoites once these mice were exposed to live Plasmodium berghei (Pichugin 
et al., 2018). Another recent study demonstrated the effectiveness of a novel 
peptide-based vaccine against human T-cell leukemia virus type 1 (HTLV-1) in 
vivo (Mulherkar et al., 2018). 
 
Isolating peptides that can be good candidates for use in a peptide vaccine is a 
difficult process involving repeated assays for MHC binding and T-cell 
recognition in vitro. Researchers have recently been working to develop 
computational methods for predicting candidate peptides for vaccine formulation 
based on the compiled results of laboratory assays. Although these methods are 
currently not very accurate, they are at a point where they can assist in the 
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vaccine design process, and they show the potential for revolutionizing vaccine 
design as prediction methods improve. 
 
TEIPPS AND RELATED THERAPIES 
Downregulation of classical MHC antigen presentation through interference with 
TAP or other means and simultaneous upregulation of MHC-E expression on the 
cellular surface appear to be a common pattern for immune escape utilized by 
HIV, hepatitis C virus (HCV), and CMV (Nattermann, Nischalke, Hofmeister, 
Ahlenstiel, et al., 2005; Nattermann, Nischalke, Hofmeister, Kupfer, et al., 2005; 
Prod’homme et al., 2012). Although downregulating classical MHC expression 
may assist in escaping the action of MHC-restricted CTLs, this may result in the 
activation of NK cells. Because HLA-E serves as a primary inhibitor of NK cell 
activity, this combined strategy can result in escape from the action of both CTLs 
and NK cells. This poses a significant challenge in finding effective therapies for 
these viruses.  
 
Researchers have discovered that certain peptides presented through TAP-
independent processing pathways can be used to characterize cells that do not 
have functional TAP complexes. In the absence of functional TAP protein, a 
limited set of housekeeping protein fragments are predominantly displayed 
through MHC. This situation with protein fragments does not occur to an 
appreciable degree in cells with functional TAP. The term TEIPP (T-cell epitopes 
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associated with impaired peptide processing) has been coined to refer to these 
peptides.  
 
Studies have shown that T cells are capable of recognizing these TEIPP 
peptides when they are presented by means of MHC-I. Thus, it is possible to 
develop immunotherapies to help the immune system recognize and target TAP-
deficient cells such as cancer cells that have downregulated TAP expression or 
virally infected cells that have inhibited TAP function (Marijt et al., 2018). One 
study has already demonstrated the possibility of establishing a CTL culture 
capable of specifically targeting TAP-deficient cells in vivo in a mouse model 
(Hall et al., 2006). 
 
ONCOLYTIC VIRUSES AND VIRUSES AS LIVE VACCINES  
Previous studies have investigated the potential of oncolytic viruses, or viruses 
designed to specifically infect and destroy cancerous cells. Although the 
destruction of cancerous cells can be accomplished in part by the viruses 
themselves as they replicate and lyse host cells, viral activity alone may not be 
enough to completely eliminate tumor tissue, especially in the presence of a 
competent immune system (Toda et al., 1999). Certainly, the presence of a viral 
infection can lead to increased immune activation, release of inflammatory 
cytokines, and targeting of the immune system to the tumor microenvironment; 
however, there is more that genetically engineered viruses can offer. Engineering 
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these viruses to express prominent pathogen-derived antigens at a high level can 
result in live virus vaccines that assist in the cross-presentation process, priming 
CTLs to recognize and target infected cells. 
 
In the context of HIV being generally efficient at defeating MHC class IA-
mediated immunity, researchers have recently explored options for utilizing 
alternative peptide processing pathways to open a new surface of attack against 
HIV. As previously discussed, cytomegalovirus (CMV) expresses immunoevasins 
which are capable of downregulating MHC class IA expression and upregulating 
MHC-E expression. Because MHC-E has a rigid, open peptide binding groove, it 
is stable in the absence of bound peptide, and this stability facilitates peptide 
exchange. Thus, although CMV is able to escape detection by NK cells by 
upregulating MHC-E expression, it may also increase the presentation of 
peptides, some of which may be CMV antigens, by means of MHC-E (Hansen et 
al., 2016). 
 
RhCMV (a relative of CMV that specifically infects rhesus macaques) has been 
shown to mitigate this risk by interfering with CTL responses, leading CTLs to 
respond to nonconventional epitopes. In effect, this prevents CTLs from 
responding to conventional CMV epitopes that would lead to an effective immune 
response. Although this property works specifically in favor of RhCMV, it can be 
leveraged for use by enabling alternate means for the immune system to target 
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other pathogens that are generally able to escape conventional immune 
responses.  
 
For example, researchers designed a modified non-attenuated rhesus 
cytomegalovirus (RhCMV) vector which expressed antigens of simian 
immunodeficiency virus (SIV), a relative of HIV. These researchers then 
administered the RhCMV vector to rhesus macaques. The vector was able to 
form a stable infection within the rhesus macaques and to elicit priming of CTLs 
to nonconventional SIV epitopes. Thus, when these rhesus macaques were 
subsequently exposed to SIV, they were able to mount an effective immune 
response because the CTLs were primed and restricted to an epitope for which 
SIV had not evolved an adequate escape mechanism. Ultimately, 12 out of 24 
rhesus macaques were able to successfully resist the infection (undetectable 
plasma viral RNA) for more than a year (Hansen et al., 2011).  
 
Similarly, a study using a modified non-attenuated rhesus cytomegalovirus 
(RhCMV) to deliver Plasmodium antigens to CTLs in a rhesus macaque host 
demonstrated a 75%–80% reduction of merozoite release from the host liver 
following infection. This was consistent with the elicitation of an effective 
nonconventional CTL-mediated immune response to liver-stage Plasmodium 




NATURAL KILLER CELL TREATMENTS 
Cells with no functional MHC-I mediated antigen presentation can be especially 
problematic for the immune system to manage. One remedy for this situation is 
to find a way to restore functionality of the MHC-I system. In one study, tumor 
cells with a beta-2-microglobulin deficiency were treated with a viral vector 
carrying a functional copy of the beta-2-microglobulin (del Campo et al., 2009). 
This simple strategy was able to restore lasting function of MHC-I mediated 
antigen presentation in the target cells. Nevertheless, there is little to suggest 
that the tumor cells could not simply develop the means of downregulating or 
deleting the replacement beta-2-microglobulin gene at a later point in time. 
 
Fortunately, a more powerful mechanism already exists within the immune 
system to handle MHC-I deficient cells: NK cells. However, pathogens such as 
HIV, HCV, and CMV, which have developed a way to disable MHC-I mediated 
antigen presentation, may also be able to mitigate the effectiveness of natural 
killer cells. Research has shown that MHC-I deficient tumor cells can cause NK 
cells to assume a low energy state in which they fail to eliminate the tumor cells. 
It is unclear whether this is a result of the NK cells becoming in some way 
overwhelmed or deactivated by the volume of cells not expressing MHC-I or the 
cancer cells themselves playing an active role in eliciting this low energy state in 
the NK cells. Regardless of the etiology of this change, the research 
demonstrated that treatment with cytokines can help restore NK cell activity in 
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vitro. The study also suggested that a similar cytokine treatment may be able to 
reactivate NK cells in vivo and enable them to effectively target MHC class I-
deficient cancer cells (Ardolino et al., 2014). 
 
Rather than treating patients with cytokines directly, an adoptive cell therapy 
(ACT) approach can be taken to deliver preactivated NK cells to the patient. One 
study was able to demonstrate increased antitumor activity by NK cells 
pretreated with a mixture of cytokines in a mouse model, especially when the 
treatment was combined with radiation therapy (Ni et al., 2012). Adoptive cell 
therapies utilizing NK cells have an advantage over those using CTLs in that NK 
cells are not restricted to host MHC proteins like CTLs. NK cells are by nature 
nonhost specific and simply target any cell that does not present MHC class I 
protein for destruction. For this reason, it would be possible to develop cultures of 
preactivated NK cells that can be used broadly between patients to good effect 
without concern of issues with MHC compatibility. This could greatly reduce the 
cost and time investment currently involved in adoptive cell therapies, which 
typically require a CTL culture to be developed on a patient-by-patient basis (Liu 
et al., 2018). Furthermore, studies trialing CAR NK-cell therapies have recently 
begun to emerge, and the results so far seem to indicate that CAR NK-cell 
therapies may hold even more promise against certain cancers than CAR T-cell 





A successful immune response against intracellular pathogens relies upon 
effective epitope presentation by MHC-I and recognition by CTLs. Therefore, 
addressing weaknesses in this system in a comprehensive manner is a 
worthwhile pursuit. Immunotherapy has only begun to scratch the surface of the 
potential of the human immune system. Given the successes found through 
immunotherapies thus far, it is clear that the immune system, when functioning 
properly, can be more effective and flexible in combating infection than any other 
treatment which can be developed with current technology. Moreover, the 
immune system can function in this role with minimal side effects or risk to the 
patient. Although many immunotherapies are currently expensive and generally 
impractical for use against viruses and infections that can be managed through 
other means, with time, immunotherapies may become refined to the degree that 
their use can be expanded beyond treating cancers. In the future, 
immunotherapy techniques can be coordinated with patient-specific vaccines to 
elicit a maximally effective and highly specific immune response. The 
establishment of a comprehensive, inexpensive, and safe multitiered protocol for 
the management of immune-evading pathogens must be made a priority in future 
research efforts.  
 
For the first tier of immune evasion in which MHC-I mediated antigen 
presentation remains entirely intact but the immune system fails to reliably 
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recognize infected cells, many options are available for treatment. Research 
continues to advance methods with which to facilitate cross-presentation of 
pathogen-derived antigens by APCs and targeting of infected cells by effector 
CTLs. Peptide-based vaccines will likely remain the most appealing option 
among all the others given their low cost and practicality, though issues with their 
efficacy need to be fully resolved. Alternatively, ACT of APCs themselves can be 
a more efficacious though less practical option. APC ACT bypasses some of the 
limitations of peptide-based vaccines because antigens can be administered 
directly to the APCs prior to infusion, thereby guaranteeing that cross-
presentation will occur successfully. Live vaccines in the form of recombinant 
viruses can also be considered because they provide a steady stream of 
antigenic proteins for cross-presentation by APCs. Live vaccines, utilizing CMV in 
particular, warrant further evaluation because they can help prevent immune 
escape through altering patterns of antigen presentation by MHC and patterns of 
antigen recognition in CTLs. However, caution must be taken when administering 
recombinant viruses that have the infectious capability of CMV because there is 
a risk of unintended effects. It is worth considering that given the potential for 
antigenic drift among infectious agents, especially viruses, treatments must 
target multiple separate antigens to prevent the possibility of immune escape. 
This study summarized only a subset of the many methods that have been 
explored for enhancing cross-presentation and MHC class I-mediated immunity. 
As refinement continues of these current strategies, there remains ample room to 
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explore further ways in which the functionality of these immune pathways can be 
facilitated. For example, one recent and novel study tested a method of 
converting red blood cells into artificial APCs (Sun et al., 2017).  
 
In a second tier of immune evasion in which TAP or classical MHC function is 
limited by mutation, deletion, or the actions of an immunoevasin, a different set of 
treatments must be explored. TAP-deficient cells present unique peptides known 
as TEIPPs, which can themselves serve as epitopes for MHC restriction and 
CTL-mediated lysis of infected cells. Methods must be explored more thoroughly 
in which this property of TAP-deficient cells, either through ACT or preferably 
vaccines, can be utilized. Because limited TAP function significantly 
downregulates the expression of MHC class IA proteins on the cellular surface, 
further research must be carried out on MHC  class IB proteins, particularly on 
how to develop vaccines and ACT therapies that target the epitopes which they 
can present. NK cell-mediated therapies could also prove fruitful in the case of 
MHC or TAP downregulation; however, in the case of viruses such as HIV, HCV, 
and CMV that upregulate MHC-E expression, a strategy must be devised to 
overcome this protective mechanism. 
 
Although many immunotherapy techniques, such as peptide-based vaccines, live 
vaccines, and ACT, work to address the weaknesses of MHC-I antigen 
presentation and APC cross-presentation systems, CAR cell therapies seek to 
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entirely bypass the need for a functional MHC-I antigen presentation system. 
This is an attractive option in circumstances in which the MHC-I antigen 
presentation system has been rendered completely nonfunctional. Cost and 
impracticality have historically been limiting factors in the application of CAR cell 
therapies; however, new options are being explored to reduce the cost of these 
therapies (Shrestha et al., 2019). CAR cell therapies also have an innate 
limitation in that they rely on the ability to find proteins expressed on the cellular 
surface which are specific to infected cells. Although some cancers are well 
known for expressing mutant receptor proteins at high levels on the cellular 
surface and as a result serve as excellent targets for CAR cell therapies, finding 
target surface antigens for treating cells infected with viruses, bacteria, or fungi 
may prove to be less simple. Nevertheless, even among this group, viable 
targets for CAR cell therapies remain (Figure 6). For example, anti-HIV CAR T-
cell therapies have been in development since at least 1994, and after many 
revisions and advancements to the design of these therapies, recent studies 
have demonstrated long-lasting and complete control of HIV in large-scale 
animal models (Roberts et al., 1994; Zhen et al., 2017). Meanwhile, additional 
studies have had varying success in exploring the use of CAR cell therapies for 
treating CMV, hepatitis B virus (HBV), HCV, EBV, and others (Bohne et al., 2008; 
Full et al., 2010; Kruse et al., 2018; Tang et al., 2014). Thus, although CAR cell 
therapies are still expensive, limited in scope, and impractical for widespread 
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use, they currently remain one of the most promising and effective methods for 
the control of immune evasive pathogens. 
 
Although diseases such as tuberculosis, malaria, HIV, and cancer may differ in 
many fundamental ways, it has become clear that the future of treating these 
elusive pathogens must involve utilization of the tools provided in the human 
immune system. As advancements in research continue in the field of 
immunology, the applicability of therapies developed for treating cancer may 
begin to overlap with those devised for treating viruses or parasites, and likewise, 
treatments effective in helping the immune system to eliminate viruses and 
bacteria may become relevant in cancer treatment. Thus, the importance of 
cross-discipline collaboration in the development of new therapies must be 
emphasized above all. With the combined resources of many previously 
disparate fields now gathering under the single umbrella of immunotherapy, there 























Figure 6. Depiction of various CAR T-cell therapies and their mechanisms 
of action. This figure shows T cells bearing CARs interacting with various cell 
surface antigens on cells infected with HIV, HBV, HCV, CMV, and Aspergillis 
fumigatus. CAR = Chimeric Antigen Receptor; CD = Cluster of Differentiation; 
CMV = Cytomegalovirus; HBV = Hepatitis B Virus; HCV = Hepatitis C Virus ; HIV 







Abdulhaqq, S. A., Wu, H., Schell, J. B., Hammond, K. B., Reed, J. S., Legasse, 
A. W., Axthelm, M. K., Park, B. S., Asokan, A., Früh, K., Hansen, S. G., 
Picker, L. J., & Sacha, J. B. (2019). Vaccine-Mediated Inhibition of the 
Transporter Associated with Antigen Processing Is Insufficient To Induce 
Major Histocompatibility Complex E-Restricted CD8+ T Cells in 
Nonhuman Primates. Journal of Virology, 93(19). 
https://doi.org/10.1128/JVI.00592-19 
 
Ahn, K., Gruhler, A., Galocha, B., Jones, T. R., Wiertz, E. J., Ploegh, H. L., 
Peterson, P. A., Yang, Y., & Früh, K. (1997). The ER-luminal domain of 
the HCMV glycoprotein US6 inhibits peptide translocation by TAP. 
Immunity, 6(5), 613–621. https://doi.org/10.1016/s1074-7613(00)80349-0 
 
Albanese, M., Tagawa, T., Bouvet, M., Maliqi, L., Lutter, D., Hoser, J., Hastreiter, 
M., Hayes, M., Sugden, B., Martin, L., Moosmann, A., & Hammerschmidt, 
W. (2016). Epstein-Barr virus microRNAs reduce immune surveillance by 
virus-specific CD8+ T cells. Proceedings of the National Academy of 
Sciences of the United States of America, 113(42), E6467–E6475. 
https://doi.org/10.1073/pnas.1605884113 
 
Alberts, B., Johnson, A., Lewis, J., Morgan, D., Raff, M., Roberts, K., & Walter, P. 
(2015). Molecular biology of the cell (6th ed.). Garland Science. 
 
Amino, R., Thiberge, S., Martin, B., Celli, S., Shorte, S., Frischknecht, F., & 
Ménard, R. (2006). Quantitative imaging of Plasmodium transmission from 
mosquito to mammal. Nature Medicine, 12(2), 220–224. 
https://doi.org/10.1038/nm1350 
 
Ardeniz, Ö., Unger, S., Onay, H., Ammann, S., Keck, C., Cianga, C., Gerçeker, 
B., Martin, B., Fuchs, I., Salzer, U., İkincioğulları, A., Güloğlu, D., Dereli, 
T., Thimme, R., Ehl, S., Schwarz, K., Schmitt-Graeff, A., Cianga, P., Fisch, 
P., & Warnatz, K. (2015). Β2-Microglobulin deficiency causes a complex 
immunodeficiency of the innate and adaptive immune system. The Journal 
of Allergy and Clinical Immunology, 136(2), 392–401. 
https://doi.org/10.1016/j.jaci.2014.12.1937 
 
Ardolino, M., Azimi, C. S., Iannello, A., Trevino, T. N., Horan, L., Zhang, L., Deng, 
W., Ring, A. M., Fischer, S., Garcia, K. C., & Raulet, D. H. (2014). 
Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. The 
 
49 
Journal of Clinical Investigation, 124(11), 4781–4794. 
https://doi.org/10.1172/JCI74337 
Bachmann, M. F., Oxenius, A., Pircher, H., Hengartner, H., Ashton-Richardt, P. 
A., Tonegawa, S., & Zinkernagel, R. M. (1995). TAP1-independent loading 
of class I molecules by exogenous viral proteins. European Journal of 
Immunology, 25(6), 1739–1743. https://doi.org/10.1002/eji.1830250637 
 
Bern, M. D., Parikh, B. A., Yang, L., Beckman, D. L., Poursine-Laurent, J., & 
Yokoyama, W. M. (2019). Inducible down-regulation of MHC class I 
results in natural killer cell tolerance. The Journal of Experimental 
Medicine, 216(1), 99–116. https://doi.org/10.1084/jem.20181076 
 
Bernecker, C., Ostapczuk, M., Vordenbäumen, S., Ehlers, M., Thiel, A., 
Schinner, S., Willenberg, H., Scherbaum, W. A., & Schott, M. (2013). HLA-
A2 phenotype may be protective against Graves’ disease but not against 
Hashimoto’s thyroiditis in Caucasians. Hormone and Metabolic Research 
= Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, 
45(1), 74–77. https://doi.org/10.1055/s-0032-1323704 
 
Bian, Y., Shang, S., Siddiqui, S., Zhao, J., Joosten, S. A., Ottenhoff, T. H. M., 
Cantor, H., & Wang, C.-R. (2017). MHC Ib molecule Qa-1 presents 
Mycobacterium tuberculosis peptide antigens to CD8+ T cells and 
contributes to protection against infection. PLoS Pathogens, 13(5), 
e1006384. https://doi.org/10.1371/journal.ppat.1006384 
 
Bijker, M. S., van den Eeden, S. J. F., Franken, K. L., Melief, C. J. M., van der 
Burg, S. H., & Offringa, R. (2008). Superior induction of anti-tumor CTL 
immunity by extended peptide vaccines involves prolonged, DC-focused 
antigen presentation. European Journal of Immunology, 38(4), 1033–
1042. https://doi.org/10.1002/eji.200737995 
 
Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L., & 
Wiley, D. C. (1987). Structure of the human class I histocompatibility 
antigen, HLA-A2. Nature, 329(6139), 506–512. 
https://doi.org/10.1038/329506a0 
 
Blees, A., Januliene, D., Hofmann, T., Koller, N., Schmidt, C., Trowitzsch, S., 
Moeller, A., & Tampé, R. (2017). Structure of the human MHC-I peptide-
loading complex. Nature, 551(7681), 525–528. 
https://doi.org/10.1038/nature24627 
 
Bohne, F., Chmielewski, M., Ebert, G., Wiegmann, K., Kürschner, T., Schulze, 
A., Urban, S., Krönke, M., Abken, H., & Protzer, U. (2008). T cells 
redirected against hepatitis B virus surface proteins eliminate infected 
 
50 
hepatocytes. Gastroenterology, 134(1), 239–247. 
https://doi.org/10.1053/j.gastro.2007.11.002 
Borghans, J. A. M., Beltman, J. B., & De Boer, R. J. (2004). MHC polymorphism 
under host-pathogen coevolution. Immunogenetics, 55(11), 732–739. 
https://doi.org/10.1007/s00251-003-0630-5 
 
Braud, V. M., Allan, D. S., O’Callaghan, C. A., Söderström, K., D’Andrea, A., 
Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., Lanier, L. L., 
& McMichael, A. J. (1998). HLA-E binds to natural killer cell receptors 
CD94/NKG2A, B and C. Nature, 391(6669), 795–799. 
https://doi.org/10.1038/35869 
 
Brown, G., Biberfeld, P., Christensson, B., & Mason, D. Y. (1979). The 
distribution of HLA on human lymphoid, bone marrow and peripheral blood 
cells. European Journal of Immunology, 9(4), 272–275. 
https://doi.org/10.1002/eji.1830090405 
 
Brown, J. H., Jardetzky, T. S., Gorga, J. C., Stern, L. J., Urban, R. G., 
Strominger, J. L., & Wiley, D. C. (1993). Three-dimensional structure of 
the human class II histocompatibility antigen HLA-DR1. Nature, 
364(6432), 33–39. https://doi.org/10.1038/364033a0 
 
Cabrera, T., Angustias Fernandez, M., Sierra, A., Garrido, A., Herruzo, A., 
Escobedo, A., Fabra, A., & Garrido, F. (1996). High frequency of altered 
HLA class I phenotypes in invasive breast carcinomas. Human 
Immunology, 50(2), 127–134. https://doi.org/10.1016/0198-
8859(96)00145-0 
 
Cabrera, T., Salinero, J., Fernandez, M. A., Garrido, A., Esquivias, J., & Garrido, 
F. (2000). High frequency of altered HLA class I phenotypes in laryngeal 
carcinomas. Human Immunology, 61(5), 499–506. 
https://doi.org/10.1016/s0198-8859(00)00097-5 
 
Cantor, H. M., & Dumont, A. E. (1967). Hepatic suppression of sensitization to 
antigen absorbed into the portal system. Nature, 215(5102), 744–745. 
https://doi.org/10.1038/215744a0 
 
Chang, S.-C., Momburg, F., Bhutani, N., & Goldberg, A. L. (2005). The ER 
aminopeptidase, ERAP1, trims precursors to lengths of MHC class I 
peptides by a “molecular ruler” mechanism. Proceedings of the National 







Chapman, T. L., Heikeman, A. P., & Bjorkman, P. J. (1999). The inhibitory 
receptor LIR-1 uses a common binding interaction to recognize class I 
MHC molecules and the viral homolog UL18. Immunity, 11(5), 603–613. 
https://doi.org/10.1016/s1074-7613(00)80135-1 
 
Chu, X., Pan, C.-M., Zhao, S.-X., Liang, J., Gao, G.-Q., Zhang, X.-M., Yuan, G.-
Y., Li, C.-G., Xue, L.-Q., Shen, M., Liu, W., Xie, F., Yang, S.-Y., Wang, H.-
F., Shi, J.-Y., Sun, W.-W., Du, W.-H., Zuo, C.-L., Shi, J.-X., … China 
Consortium for Genetics of Autoimmune Thyroid Disease. (2011). A 
genome-wide association study identifies two new risk loci for Graves’ 
disease. Nature Genetics, 43(9), 897–901. https://doi.org/10.1038/ng.898 
 
Curtidor, H., Reyes, C., Bermúdez, A., Vanegas, M., Varela, Y., & Patarroyo, M. 
E. (2017). Conserved Binding Regions Provide the Clue for Peptide-
Based Vaccine Development: A Chemical Perspective. Molecules : A 
Journal of Synthetic Chemistry and Natural Product Chemistry, 22(12). 
https://doi.org/10.3390/molecules22122199 
 
Das, K., Eisel, D., Lenkl, C., Goyal, A., Diederichs, S., Dickes, E., Osen, W., & 
Eichmüller, S. B. (2017). Generation of murine tumor cell lines deficient in 
MHC molecule surface expression using the CRISPR/Cas9 system. PloS 
One, 12(3), e0174077. https://doi.org/10.1371/journal.pone.0174077 
 
de la Salle, H., Saulquin, X., Mansour, I., Klayme, S., Fricker, D., Zimmer, J., 
Cazenave, J.-P., Hanau, D., Bonneville, M., Houssaint, E., Lefranc, G., & 
Naman, R. (2002). Asymptomatic deficiency in the peptide transporter 
associated to antigen processing (TAP). Clinical and Experimental 
Immunology, 128(3), 525–531. https://doi.org/10.1046/j.1365-
2249.2002.01862.x 
 
de la Salle, H., Zimmer, J., Fricker, D., Angenieux, C., Cazenave, J. P., Okubo, 
M., Maeda, H., Plebani, A., Tongio, M. M., Dormoy, A., & Hanau, D. 
(1999). HLA class I deficiencies due to mutations in subunit 1 of the 
peptide transporter TAP1. The Journal of Clinical Investigation, 103(5), 
R9–R13. https://doi.org/10.1172/JCI5687 
 
del Campo, A. B., Aptsiauri, N., Méndez, R., Zinchenko, S., Vales, A., Paschen, 
A., Ward, S., Ruiz-Cabello, F., González-Aseguinolaza, G., & Garrido, F. 
(2009). Efficient recovery of HLA class I expression in human tumor cells 
after beta2-microglobulin gene transfer using adenoviral vector: 
Implications for cancer immunotherapy. Scandinavian Journal of 






Del Mar Valenzuela-Membrives, M., Perea-García, F., Sanchez-Palencia, A., 
Ruiz-Cabello, F., Gómez-Morales, M., Miranda-León, M. T., Galindo-
Angel, I., & Fárez-Vidal, M. E. (2016). Progressive changes in composition 
of lymphocytes in lung tissues from patients with non-small-cell lung 
cancer. Oncotarget, 7(44), 71608–71619. 
https://doi.org/10.18632/oncotarget.12264 
 
Dong, Q., Shi, B., Zhou, M., Gao, H., Luo, X., Li, Z., & Jiang, H. (2019). Growth 
suppression of colorectal cancer expressing S492R EGFR by monoclonal 
antibody CH12. Frontiers of Medicine, 13(1), 83–93. 
https://doi.org/10.1007/s11684-019-0682-z 
 
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993). Specific activation 
and targeting of cytotoxic lymphocytes through chimeric single chains 
consisting of antibody-binding domains and the gamma or zeta subunits of 
the immunoglobulin and T-cell receptors. Proceedings of the National 
Academy of Sciences of the United States of America, 90(2), 720–724. 
 
Falk, K., Rötzschke, O., Stevanović, S., Jung, G., & Rammensee, H. G. (1991). 
Allele-specific motifs revealed by sequencing of self-peptides eluted from 
MHC molecules. Nature, 351(6324), 290–296. 
https://doi.org/10.1038/351290a0 
 
Feenstra, M., Veltkamp, M., van Kuik, J., Wiertsema, S., Slootweg, P., van den 
Tweel, J., de Weger, R., & Tilanus, M. (1999). HLA class I expression and 
chromosomal deletions at 6p and 15q in head and neck squamous cell 
carcinomas. Tissue Antigens, 54(3), 235–245. 
https://doi.org/10.1034/j.1399-0039.1999.540304.x 
 
Feinstein, L., Douglas, C. E., Stebbins, R. C., Pawelec, G., Simanek, A. M., & 
Aiello, A. E. (2016). Does cytomegalovirus infection contribute to 
socioeconomic disparities in all-cause mortality? Mechanisms of Ageing 
and Development, 158, 53–61. https://doi.org/10.1016/j.mad.2016.06.001 
 
Ferreiro-Iglesias, A., Lesseur, C., McKay, J., Hung, R. J., Han, Y., Zong, X., 
Christiani, D., Johansson, M., Xiao, X., Li, Y., Qian, D. C., Ji, X., Liu, G., 
Caporaso, N., Scelo, G., Zaridze, D., Mukeriya, A., Kontic, M., Ognjanovic, 
S., … Brennan, P. (2018). Fine mapping of MHC region in lung cancer 
highlights independent susceptibility loci by ethnicity. Nature 





Flomenberg, N., Baxter-Lowe, L. A., Confer, D., Fernandez-Vina, M., Filipovich, 
A., Horowitz, M., Hurley, C., Kollman, C., Anasetti, C., Noreen, H., 
Begovich, A., Hildebrand, W., Petersdorf, E., Schmeckpeper, B., 
Setterholm, M., Trachtenberg, E., Williams, T., Yunis, E., & Weisdorf, D. 
(2004). Impact of HLA class I and class II high-resolution matching on 
outcomes of unrelated donor bone marrow transplantation: HLA-C 
mismatching is associated with a strong adverse effect on transplantation 
outcome. Blood, 104(7), 1923–1930. https://doi.org/10.1182/blood-2004-
03-0803 
 
Forget, M.-A., Haymaker, C., Hess, K. R., Meng, Y. J., Creasy, C., Karpinets, T., 
Fulbright, O. J., Roszik, J., Woodman, S. E., Kim, Y. U., Sakellariou-
Thompson, D., Bhatta, A., Wahl, A., Flores, E., Thorsen, S. T., Tavera, R. 
J., Ramachandran, R., Gonzalez, A. M., Toth, C. L., … Bernatchez, C. 
(2018). Prospective Analysis of Adoptive TIL Therapy in Patients with 
Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers 
to Predict Clinical Outcome. Clinical Cancer Research: An Official Journal 
of the American Association for Cancer Research, 24(18), 4416–4428. 
https://doi.org/10.1158/1078-0432.CCR-17-3649 
 
Frey, B. F., Jiang, J., Sui, Y., Boyd, L. F., Yu, B., Tatsuno, G., Billeskov, R., 
Solaymani-Mohammadi, S., Berman, P. W., Margulies, D. H., & Berzofsky, 
J. A. (2018). Effects of Cross-Presentation, Antigen Processing, and 
Peptide Binding in HIV Evasion of T Cell Immunity. Journal of Immunology 
(Baltimore, Md.: 1950), 200(5), 1853–1864. 
https://doi.org/10.4049/jimmunol.1701523 
 
Full, F., Lehner, M., Thonn, V., Goetz, G., Scholz, B., Kaufmann, K. B., Mach, M., 
Abken, H., Holter, W., & Ensser, A. (2010). T cells engineered with a 
cytomegalovirus-specific chimeric immunoreceptor. Journal of Virology, 
84(8), 4083–4088. https://doi.org/10.1128/JVI.02117-09 
 
Garcia‐Lora, A., Algarra, I., & Garrido, F. (2003). MHC class I antigens, immune 
surveillance, and tumor immune escape. Journal of Cellular Physiology, 
195(3), 346–355. https://doi.org/10.1002/jcp.10290 
 
Gomard, E., Begue, B., Sodoyer, S., Maryanski, J. L., Jordan, B. R., & Levy, J. P. 
(1986). Murine cells expressing an HLA molecule are specifically lysed by 







Hall, T. van, Wolpert, E. Z., Veelen, P. van, Laban, S., Veer, M. van der, 
Roseboom, M., Bres, S., Grufman, P., Ru, A. de, Meiring, H., Jong, A. de, 
Franken, K., Teixeira, A., Valentijn, R., Drijfhout, J. W., Koning, F., Camps, 
M., Ossendorp, F., Kärre, K., … Offringa, R. (2006). Selective cytotoxic T-
lymphocyte targeting of tumor immune escape variants. Nature Medicine, 
12(4), 417–424. https://doi.org/10.1038/nm1381 
 
Hansen, S. G., Ford, J. C., Lewis, M. S., Ventura, A. B., Hughes, C. M., Coyne-
Johnson, L., Whizin, N., Oswald, K., Shoemaker, R., Swanson, T., 
Legasse, A. W., Chiuchiolo, M. J., Parks, C. L., Axthelm, M. K., Nelson, J. 
A., Jarvis, M. A., Piatak, M., Lifson, J. D., & Picker, L. J. (2011). Profound 
early control of highly pathogenic SIV by an effector memory T-cell 
vaccine. Nature, 473(7348), 523–527. https://doi.org/10.1038/nature10003 
 
Hansen, S. G., Sacha, J. B., Hughes, C. M., Ford, J. C., Burwitz, B. J., Scholz, I., 
Gilbride, R. M., Lewis, M. S., Gilliam, A. N., Ventura, A. B., Malouli, D., Xu, 
G., Richards, R., Whizin, N., Reed, J. S., Hammond, K. B., Fischer, M., 
Turner, J. M., Legasse, A. W., … Picker, L. J. (2013). Cytomegalovirus 
vectors violate CD8+ T cell epitope recognition paradigms. Science (New 
York, N.Y.), 340(6135), 1237874. https://doi.org/10.1126/science.1237874 
 
Hansen, S. G., Womack, J., Scholz, I., Renner, A., Edgel, K. A., Xu, G., Ford, J. 
C., Grey, M., St Laurent, B., Turner, J. M., Planer, S., Legasse, A. W., 
Richie, T. L., Aguiar, J. C., Axthelm, M. K., Villasante, E. D., Weiss, W., 
Edlefsen, P. T., Picker, L. J., & Früh, K. (2019). Cytomegalovirus vectors 
expressing Plasmodium knowlesi antigens induce immune responses that 
delay parasitemia upon sporozoite challenge. PloS One, 14(1), e0210252. 
https://doi.org/10.1371/journal.pone.0210252 
 
Hansen, S. G., Wu, H. L., Burwitz, B. J., Hughes, C. M., Hammond, K. B., 
Ventura, A. B., Reed, J. S., Gilbride, R. M., Ainslie, E., Morrow, D. W., 
Ford, J. C., Selseth, A. N., Pathak, R., Malouli, D., Legasse, A. W., 
Axthelm, M. K., Nelson, J. A., Gillespie, G. M., Walters, L. C., … Picker, L. 
J. (2016). Broadly targeted CD8+ T cell responses restricted by major 
histocompatibility complex E. Science (New York, N.Y.), 351(6274), 714–
720. https://doi.org/10.1126/science.aac9475 
 
Huard, B., & Früh, K. (2000). A role for MHC class I down-regulation in NK cell 







Ingegnere, T., Mariotti, F. R., Pelosi, A., Quintarelli, C., De Angelis, B., Tumino, 
N., Besi, F., Cantoni, C., Locatelli, F., Vacca, P., & Moretta, L. (2019). 
Human CAR NK Cells: A New Non-viral Method Allowing High Efficient 
Transfection and Strong Tumor Cell Killing. Frontiers in Immunology, 10, 
957. https://doi.org/10.3389/fimmu.2019.00957 
 
Irvine, D. J., Purbhoo, M. A., Krogsgaard, M., & Davis, M. M. (2002). Direct 
observation of ligand recognition by T cells. Nature, 419(6909), 845–849. 
https://doi.org/10.1038/nature01076 
 
Jameson, S. C., Hogquist, K. A., & Bevan, M. J. (1994). Specificity and flexibility 
in thymic selection. Nature, 369(6483), 750–752. 
https://doi.org/10.1038/369750a0 
 
Jones, T. R., Wiertz, E. J., Sun, L., Fish, K. N., Nelson, J. A., & Ploegh, H. L. 
(1996). Human cytomegalovirus US3 impairs transport and maturation of 
major histocompatibility complex class I heavy chains. Proceedings of the 
National Academy of Sciences of the United States of America, 93(21), 
11327–11333. https://doi.org/10.1073/pnas.93.21.11327 
 
King, C. R., Kraus, M. H., & Aaronson, S. A. (1985). Amplification of a novel v-
erbB-related gene in a human mammary carcinoma. Science (New York, 
N.Y.), 229(4717), 974–976. https://doi.org/10.1126/science.2992089 
 
Koch, J., Guntrum, R., Heintke, S., Kyritsis, C., & Tampé, R. (2004). Functional 
dissection of the transmembrane domains of the transporter associated 
with antigen processing (TAP). The Journal of Biological Chemistry, 
279(11), 10142–10147. https://doi.org/10.1074/jbc.M312816200 
 
Kruse, R. L., Shum, T., Tashiro, H., Barzi, M., Yi, Z., Whitten-Bauer, C., Legras, 
X., Bissig-Choisat, B., Garaigorta, U., Gottschalk, S., & Bissig, K.-D. 
(2018). HBsAg-redirected T cells exhibit antiviral activity in HBV-infected 
human liver chimeric mice. Cytotherapy, 20(5), 697–705. 
https://doi.org/10.1016/j.jcyt.2018.02.002 
 
Lavi, E., Das Sarma, J., & Weiss, S. R. (1999). Cellular reservoirs for coronavirus 
infection of the brain in beta2-microglobulin knockout mice. Pathobiology: 








Le, D. T., Lutz, E., Uram, J. N., Sugar, E. A., Onners, B., Solt, S., Zheng, L., 
Diaz, L. A., Donehower, R. C., Jaffee, E. M., & Laheru, D. A. (2013). 
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor 
cells transfected with a GM-CSF gene in previously treated pancreatic 
cancer. Journal of Immunotherapy (Hagerstown, Md.: 1997), 36(7), 382–
389. https://doi.org/10.1097/CJI.0b013e31829fb7a2 
 
Lee, N., Llano, M., Carretero, M., Ishitani, A., Navarro, F., López-Botet, M., & 
Geraghty, D. E. (1998). HLA-E is a major ligand for the natural killer 
inhibitory receptor CD94/NKG2A. Proceedings of the National Academy of 
Sciences of the United States of America, 95(9), 5199–5204. 
https://doi.org/10.1073/pnas.95.9.5199 
 
Lei, W.-Y., Hsiung, S.-C., Wen, S.-H., Hsieh, C.-H., Chen, C.-L., Wallace, C. G., 
Chang, C.-C., & Liao, S.-K. (2018). Total HLA Class I Antigen Loss with 
the Downregulation of Antigen-Processing Machinery Components in Two 
Newly Established Sarcomatoid Hepatocellular Carcinoma Cell Lines. 
Journal of Immunology Research, 2018. 
https://doi.org/10.1155/2018/8363265 
 
Leslie, A. J., Pfafferott, K. J., Chetty, P., Draenert, R., Addo, M. M., Feeney, M., 
Tang, Y., Holmes, E. C., Allen, T., Prado, J. G., Altfeld, M., Brander, C., 
Dixon, C., Ramduth, D., Jeena, P., Thomas, S. A., St John, A., Roach, T. 
A., Kupfer, B., … Goulder, P. J. R. (2004). HIV evolution: CTL escape 
mutation and reversion after transmission. Nature Medicine, 10(3), 282–
289. https://doi.org/10.1038/nm992 
 
Liang, J.-H., Gao, R., Xia, Y., Gale, R. P., Chen, R.-Z., Yang, Y.-Q., Wang, L., 
Qu, X.-Y., Qiu, H.-R., Cao, L., Hong, M., Wang, R., Wang, Y., Fan, L., 
Chen, Y.-Y., Hu, Z.-B., Li, J.-Y., & Xu, W. (2016). Prognostic impact of 
Epstein-Barr virus (EBV)-DNA copy number at diagnosis in chronic 
lymphocytic leukemia. Oncotarget, 7(2), 2135–2142. 
https://doi.org/10.18632/oncotarget.6281 
 
Liu, B., Zhang, X., Zhang, W., Wu, L., Jing, S., Liu, W., Xia, B., Zou, F., Lu, L., 
Ma, X., He, D., Hu, Q., Zhang, Y., Deng, K., Cai, W., Tang, X., Peng, T., 
Zhang, H., & Li, L. (2019). Lovastatin Inhibits HIV-1-Induced MHC-I 
Downregulation by Targeting Nef-AP-1 Complex Formation: A New 
Strategy to Boost Immune Eradication of HIV-1 Infected Cells. Frontiers in 






Liu, E., Tong, Y., Dotti, G., Shaim, H., Savoldo, B., Mukherjee, M., Orange, J., 
Wan, X., Lu, X., Reynolds, A., Gagea, M., Banerjee, P., Cai, R., Bdaiwi, 
M. H., Basar, R., Muftuoglu, M., Li, L., Marin, D., Wierda, W., … Rezvani, 
K. (2018). Cord blood NK cells engineered to express IL-15 and a CD19-
targeted CAR show long-term persistence and potent antitumor activity. 
Leukemia, 32(2), 520–531. https://doi.org/10.1038/leu.2017.226 
 
Lorente, E., Palomo, C., Barnea, E., Mir, C., del Val, M., Admon, A., & López, D. 
(2019). Natural Spleen Cell Ligandome in Transporter Antigen 
Processing-Deficient Mice. Journal of Proteome Research, 18(9), 3512–
3520. https://doi.org/10.1021/acs.jproteome.9b00416 
 
Lu, W., Arraes, L. C., Ferreira, W. T., & Andrieu, J.-M. (2004). Therapeutic 
dendritic-cell vaccine for chronic HIV-1 infection. Nature Medicine, 10(12), 
1359–1365. https://doi.org/10.1038/nm1147 
 
Marijt, K. A., Blijleven, L., Verdegaal, E. M. E., Kester, M. G., Kowalewski, D. J., 
Rammensee, H.-G., Stevanović, S., Heemskerk, M. H. M., van der Burg, 
S. H., & van Hall, T. (2018). Identification of non-mutated neoantigens 
presented by TAP-deficient tumors. The Journal of Experimental 
Medicine, 215(9), 2325–2337. https://doi.org/10.1084/jem.20180577 
 
Matamoros, N., Milà, J., Llano, M., Balas, A., Vicario, J. L., Pons, J., Crespí, C., 
Martinez, N., Iglesias-Alzueta, J., & López-Botet, M. (2001). Molecular 
studies and NK cell function of a new case of TAP2 homozygous human 
deficiency. Clinical and Experimental Immunology, 125(2), 274–282. 
https://doi.org/10.1046/j.1365-2249.2001.01595.x 
 
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., 
Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., Mahnke, Y. D., 
Melenhorst, J. J., Rheingold, S. R., Shen, A., Teachey, D. T., Levine, B. 
L., June, C. H., Porter, D. L., & Grupp, S. A. (2014). Chimeric antigen 
receptor T cells for sustained remissions in leukemia. The New England 
Journal of Medicine, 371(16), 1507–1517. 
https://doi.org/10.1056/NEJMoa1407222 
 
Mégret, F., Prehaud, C., Lafage, M., Moreau, P., Rouas-Freiss, N., Carosella, E. 
D., & Lafon, M. (2007). Modulation of HLA-G and HLA-E expression in 
human neuronal cells after rabies virus or herpes virus simplex type 1 






Meng, L., Tong, J., Wang, H., Tao, C., Wang, Q., Niu, C., Zhang, X., & Gao, Q. 
(2017). PPE38 Protein of Mycobacterium tuberculosis Inhibits 
Macrophage MHC Class I Expression and Dampens CD8+ T Cell 
Responses. Frontiers in Cellular and Infection Microbiology, 7, 68. 
https://doi.org/10.3389/fcimb.2017.00068 
 
Mulherkar, R., Karabudak, A., Ginwala, R., Huang, X., Rowan, A., Philip, R., 
Murphy, E. L., Clements, D., Ndhlovu, L. C., Khan, Z. K., & Jain, P. 
(2018). In vivo and in vitro immunogenicity of novel MHC class I presented 
epitopes to confer protective immunity against chronic HTLV-1 infection. 
Vaccine, 36(33), 5046–5057. 
https://doi.org/10.1016/j.vaccine.2018.07.002 
 
Nattermann, J., Nischalke, H. D., Hofmeister, V., Ahlenstiel, G., Zimmermann, H., 
Leifeld, L., Weiss, E. H., Sauerbruch, T., & Spengler, U. (2005). The HLA-
A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression 
and inhibits cytolysis mediated by natural killer cells. The American 
Journal of Pathology, 166(2), 443–453. https://doi.org/10.1016/S0002-
9440(10)62267-5 
 
Nattermann, J., Nischalke, H. D., Hofmeister, V., Kupfer, B., Ahlenstiel, G., 
Feldmann, G., Rockstroh, J., Weiss, E. H., Sauerbruch, T., & Spengler, U. 
(2005). HIV-1 infection leads to increased HLA-E expression resulting in 
impaired function of natural killer cells. Antiviral Therapy, 10(1), 95–107. 
 
Neumeister, C., Nanan, R., Cornu, T. I., Lüder, C. G. K., ter Meulen, V., Naim, 
H., & Niewiesk, S. (2001). Measles virus and canine distemper virus target 
proteins into a TAP-independent MHC class I-restricted antigen-
processing pathway. Journal of General Virology, 82(2), 441–447. 
https://doi.org/10.1099/0022-1317-82-2-441 
 
Ni, J., Miller, M., Stojanovic, A., Garbi, N., & Cerwenka, A. (2012). Sustained 
effector function of IL-12/15/18–preactivated NK cells against established 
tumors. The Journal of Experimental Medicine, 209(13), 2351–2365. 
https://doi.org/10.1084/jem.20120944 
 
Noguchi, M., Matsumoto, K., Uemura, H., Arai, G., Eto, M., Naito, S., Ohyama, 
C., Nasu, Y., Tanaka, M., Moriya, F., Suekane, S., Matsueda, S., 
Komatsu, N., Sasada, T., Yamada, A., Kakuma, T., & Itoh, K. (2016). An 
Open-Label, Randomized Phase II Trial of Personalized Peptide 
Vaccination in Patients with Bladder Cancer that Progressed after 
Platinum-Based Chemotherapy. Clinical Cancer Research: An Official 




Nöll, A., Thomas, C., Herbring, V., Zollmann, T., Barth, K., Mehdipour, A. R., 
Tomasiak, T. M., Brüchert, S., Joseph, B., Abele, R., Oliéric, V., Wang, M., 
Diederichs, K., Hummer, G., Stroud, R. M., Pos, K. M., & Tampé, R. 
(2017). Crystal structure and mechanistic basis of a functional homolog of 
the antigen transporter TAP. Proceedings of the National Academy of 
Sciences of the United States of America, 114(4), E438–E447. 
https://doi.org/10.1073/pnas.1620009114 
 
Obara, W., Karashima, T., Takeda, K., Kato, R., Kato, Y., Kanehira, M., Takata, 
R., Inoue, K., Katagiri, T., Shuin, T., Nakamura, Y., & Fujioka, T. (2017). 
Effective induction of cytotoxic T cells recognizing an epitope peptide 
derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic 
renal cell carcinoma. Cancer Immunology, Immunotherapy: CII, 66(1), 17–
24. https://doi.org/10.1007/s00262-016-1915-5 
 
Oldham, M. L., Hite, R. K., Steffen, A. M., Damko, E., Li, Z., Walz, T., & Chen, J. 
(2016). A mechanism of viral immune evasion revealed by cryo-EM 
analysis of the TAP transporter. Nature, 529(7587), 537–540. 
https://doi.org/10.1038/nature16506 
 
Oliveira, C. C., Querido, B., Sluijter, M., de Groot, A. F., van der Zee, R., 
Rabelink, M. J. W. E., Hoeben, R. C., Ossendorp, F., van der Burg, S. H., 
& van Hall, T. (2013). New role of signal peptide peptidase to liberate C-
terminal peptides for MHC class I presentation. Journal of Immunology 
(Baltimore, Md.: 1950), 191(8), 4020–4028. 
https://doi.org/10.4049/jimmunol.1301496 
 
Orentas, R. J., Sindiri, S., Duris, C., Wen, X., He, J., Wei, J. S., Jarzembowski, 
J., & Khan, J. (2017). Paired Expression Analysis of Tumor Cell Surface 
Antigens. Frontiers in Oncology, 7, 173. 
https://doi.org/10.3389/fonc.2017.00173 
 
Pazmany, L., Mandelboim, O., Valés-Gómez, M., Davis, D. M., Reyburn, H. T., & 
Strominger, J. L. (1996). Protection from natural killer cell-mediated lysis 
by HLA-G expression on target cells. Science (New York, N.Y.), 
274(5288), 792–795. https://doi.org/10.1126/science.274.5288.792 
 
Perea, F., Bernal, M., Sánchez-Palencia, A., Carretero, J., Torres, C., Bayarri, 
C., Gómez-Morales, M., Garrido, F., & Ruiz-Cabello, F. (2017). The 
absence of HLA class I expression in non-small cell lung cancer correlates 
with the tumor tissue structure and the pattern of T cell infiltration. 




Pethe, K., Swenson, D. L., Alonso, S., Anderson, J., Wang, C., & Russell, D. G. 
(2004). Isolation of Mycobacterium tuberculosis mutants defective in the 
arrest of phagosome maturation. Proceedings of the National Academy of 
Sciences of the United States of America, 101(37), 13642–13647. 
https://doi.org/10.1073/pnas.0401657101 
 
Pichugin, A., Zarling, S., Perazzo, L., Duffy, P. E., Ploegh, H. L., & Krzych, U. 
(2018). Identification of a Novel CD8 T Cell Epitope Derived from 
Plasmodium berghei Protective Liver-Stage Antigen. Frontiers in 
Immunology, 9, 91. https://doi.org/10.3389/fimmu.2018.00091 
 
Prod’homme, V., Tomasec, P., Cunningham, C., Lemberg, M. K., Stanton, R. J., 
McSharry, B. P., Wang, E. C. Y., Cuff, S., Martoglio, B., Davison, A. J., 
Braud, V. M., & Wilkinson, G. W. G. (2012). Human cytomegalovirus UL40 
signal peptide regulates cell surface expression of the NK cell ligands 
HLA-E and gpUL18. Journal of Immunology (Baltimore, Md.: 1950), 
188(6), 2794–2804. https://doi.org/10.4049/jimmunol.1102068 
 
Proff, J., Walterskirchen, C., Brey, C., Geyeregger, R., Full, F., Ensser, A., 
Lehner, M., & Holter, W. (2016). Cytomegalovirus-Infected Cells Resist T 
Cell Mediated Killing in an HLA-Recognition Independent Manner. 
Frontiers in Microbiology, 7, 844. https://doi.org/10.3389/fmicb.2016.00844 
 
Ridge, J. P., Di Rosa, F., & Matzinger, P. (1998). A conditioned dendritic cell can 
be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature, 
393(6684), 474–478. https://doi.org/10.1038/30989 
 
Roberts, M. R., Qin, L., Zhang, D., Smith, D. H., Tran, A. C., Dull, T. J., 
Groopman, J. E., Capon, D. J., Byrn, R. A., & Finer, M. H. (1994). 
Targeting of human immunodeficiency virus-infected cells by CD8+ T 
lymphocytes armed with universal T-cell receptors. Blood, 84(9), 2878–
2889. 
 
Robinson, J., Guethlein, L. A., Cereb, N., Yang, S. Y., Norman, P. J., Marsh, S. 
G. E., & Parham, P. (2017). Distinguishing functional polymorphism from 
random variation in the sequences of >10,000 HLA-A, -B and -C alleles. 
PLoS Genetics, 13(6), e1006862. 
https://doi.org/10.1371/journal.pgen.1006862 
 
Rock, K. L., Reits, E., & Neefjes, J. (2016). Present Yourself! By MHC Class I 





Rock, K. L., Rothstein, L., Gamble, S., & Fleischacker, C. (1993). 
Characterization of antigen-presenting cells that present exogenous 
antigens in association with class I MHC molecules. Journal of 
Immunology (Baltimore, Md.: 1950), 150(2), 438–446. 
 
Rosendahl Huber, S., van Beek, J., de Jonge, J., Luytjes, W., & van Baarle, D. 
(2014). T Cell Responses to Viral Infections – Opportunities for Peptide 
Vaccination. Frontiers in Immunology, 5. 
https://doi.org/10.3389/fimmu.2014.00171 
 
RTS,S Clinical Trials Partnership. (2015). Efficacy and safety of RTS,S/AS01 
malaria vaccine with or without a booster dose in infants and children in 
Africa: Final results of a phase 3, individually randomised, controlled trial. 
Lancet (London, England), 386(9988), 31–45. 
https://doi.org/10.1016/S0140-6736(15)60721-8 
 
Sadasivan, B., Lehner, P. J., Ortmann, B., Spies, T., & Cresswell, P. (1996). 
Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of 
MHC class I molecules with TAP. Immunity, 5(2), 103–114. 
https://doi.org/10.1016/s1074-7613(00)80487-2 
 
Sake, H. J., Frenzel, A., Lucas-Hahn, A., Nowak-Imialek, M., Hassel, P., Hadeler, 
K.-G., Hermann, D., Becker, R., Eylers, H., Hein, R., Baars, W., 
Brinkmann, A., Schwinzer, R., Niemann, H., & Petersen, B. (2019). 
Possible detrimental effects of beta-2-microglobulin knockout in pigs. 
Xenotransplantation, 26(6), e12525. https://doi.org/10.1111/xen.12525 
 
Sei, J. J., Haskett, S., Kaminsky, L. W., Lin, E., Truckenmiller, M. E., Bellone, C. 
J., Buller, R. M., & Norbury, C. C. (2015). Peptide-MHC-I from 
Endogenous Antigen Outnumber Those from Exogenous Antigen, 
Irrespective of APC Phenotype or Activation. PLoS Pathogens, 11(6), 
e1004941. https://doi.org/10.1371/journal.ppat.1004941 
 
Seif, M., Einsele, H., & Löffler, J. (2019). CAR T Cells Beyond Cancer: Hope for 
Immunomodulatory Therapy of Infectious Diseases. Frontiers in 
Immunology, 10. https://doi.org/10.3389/fimmu.2019.02711 
 
Shrestha, B., Zhang, Y., Yu, B., Li, G., Boucher, J. C., Beatty, N. J., Tsai, H.-C., 
Wang, X., Mishra, A., Sweet, K., Lancet, J. E., Kelley, L., & Davila, M. L. 
(2019). Generation of Antitumor T Cells For Adoptive Cell Therapy With 
Artificial Antigen Presenting Cells. Journal of Immunotherapy 





Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., 
Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., & Norton, 
L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 
for metastatic breast cancer that overexpresses HER2. The New England 
Journal of Medicine, 344(11), 783–792. 
https://doi.org/10.1056/NEJM200103153441101 
 
Sun, X., Han, X., Xu, L., Gao, M., Xu, J., Yang, R., & Liu, Z. (2017). Surface-
Engineering of Red Blood Cells as Artificial Antigen Presenting Cells 
Promising for Cancer Immunotherapy. Small (Weinheim an Der 
Bergstrasse, Germany), 13(40). https://doi.org/10.1002/smll.201701864 
 
Suss-Toby, E., Zimmerberg, J., & Ward, G. E. (1996). Toxoplasma invasion: The 
parasitophorous vacuole is formed from host cell plasma membrane and 
pinches off via a fission pore. Proceedings of the National Academy of 
Sciences of the United States of America, 93(16), 8413–8418. 
 
Tacken, P. J., Ginter, W., Berod, L., Cruz, L. J., Joosten, B., Sparwasser, T., 
Figdor, C. G., & Cambi, A. (2011). Targeting DC-SIGN via its neck region 
leads to prolonged antigen residence in early endosomes, delayed 
lysosomal degradation, and cross-presentation. Blood, 118(15), 4111–
4119. https://doi.org/10.1182/blood-2011-04-346957 
 
Tam, J. C. H., & Jacques, D. A. (2014). Intracellular immunity: Finding the enemy 
within—how cells recognize and respond to intracellular pathogens. 
Journal of Leukocyte Biology, 96(2), 233–244. 
https://doi.org/10.1189/jlb.4RI0214-090R 
Tang, X., Zhou, Y., Li, W., Tang, Q., Chen, R., Zhu, J., & Feng, Z. (2014). T cells 
expressing a LMP1-specific chimeric antigen receptor mediate antitumor 
effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and 
in vivo. Journal of Biomedical Research, 28(6), 468–475. 
https://doi.org/10.7555/JBR.28.20140066 
 
Tavares, L. A., de Carvalho, J. V., Costa, C. S., Silveira, R. M., de Carvalho, A. 
N., Donadi, E. A., & daSilva, L. L. P. (2020). Two functional variants of AP-
1 complexes composed of either γ2 or γ1-subunits are independently 
required for MHC-I downregulation by HIV-1 Nef. Journal of Virology. 
https://doi.org/10.1128/JVI.02039-19 
 
Toda, M., Rabkin, S. D., Kojima, H., & Martuza, R. L. (1999). Herpes simplex 
virus as an in situ cancer vaccine for the induction of specific anti-tumor 




Toungoussova, O. S., Sandven, P., Mariandyshev, A. O., Nizovtseva, N. I., 
Bjune, G., & Caugant, D. A. (2002). Spread of Drug-Resistant 
Mycobacterium tuberculosis Strains of the Beijing Genotype in the 
Archangel Oblast, Russia. Journal of Clinical Microbiology, 40(6), 1930–
1937. https://doi.org/10.1128/JCM.40.6.1930-1937.2002 
 
Trunz, B. B., Fine, P., & Dye, C. (2006). Effect of BCG vaccination on childhood 
tuberculous meningitis and miliary tuberculosis worldwide: A meta-
analysis and assessment of cost-effectiveness. Lancet (London, England), 
367(9517), 1173–1180. https://doi.org/10.1016/S0140-6736(06)68507-3 
 
van Meel, E. R., Jaddoe, V. W. V., Reiss, I. K. M., van Zelm, M. C., de Jongste, 
J. C., Moll, H. A., & Duijts, L. (2020). The influence of Epstein-Barr virus 
and Cytomegalovirus on childhood respiratory health: A population-based 
prospective cohort study. Clinical and Experimental Allergy: Journal of the 
British Society for Allergy and Clinical Immunology. 
https://doi.org/10.1111/cea.13579 
 
Voeten, J. T., Rimmelzwaan, G. F., Nieuwkoop, N. J., Fouchier, R. A., & 
Osterhaus, A. D. (2001). Antigen processing for MHC class I restricted 
presentation of exogenous influenza A virus nucleoprotein by B-
lymphoblastoid cells. Clinical and Experimental Immunology, 125(3), 423–
431. https://doi.org/10.1046/j.1365-2249.2001.01613.x 
 
Voskuil, M. I., Bartek, I. L., Visconti, K., & Schoolnik, G. K. (2011). The response 
of mycobacterium tuberculosis to reactive oxygen and nitrogen species. 
Frontiers in Microbiology, 2, 105. https://doi.org/10.3389/fmicb.2011.00105 
 
Wang, F., Hou, H., Wu, S., Tang, Q., Huang, M., Yin, B., Huang, J., Liu, W., Mao, 
L., Lu, Y., & Sun, Z. (2015). Tim-3 pathway affects NK cell impairment in 
patients with active tuberculosis. Cytokine, 76(2), 270–279. 
https://doi.org/10.1016/j.cyto.2015.05.012 
 
Wang, X., Patenode, C., & Roizman, B. (2011). US3 protein kinase of HSV-1 
cycles between the cytoplasm and nucleus and interacts with programmed 
cell death protein 4 (PDCD4) to block apoptosis. Proceedings of the 
National Academy of Sciences of the United States of America, 108(35), 
14632–14636. https://doi.org/10.1073/pnas.1111942108 
 
Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R., & Ahmed, R. 
(2003). Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue 
Distribution and Results in Distinct Stages of Functional Impairment. 




White, K. L., Snyder, H. L., & Krzych, U. (1996). MHC class I-dependent 
presentation of exoerythrocytic antigens to CD8+ T lymphocytes is 
required for protective immunity against Plasmodium berghei. Journal of 
Immunology (Baltimore, Md.: 1950), 156(9), 3374–3381. 
 
Wiertz, E. J., Jones, T. R., Sun, L., Bogyo, M., Geuze, H. J., & Ploegh, H. L. 
(1996). The human cytomegalovirus US11 gene product dislocates MHC 
class I heavy chains from the endoplasmic reticulum to the cytosol. Cell, 
84(5), 769–779. https://doi.org/10.1016/s0092-8674(00)81054-5 
 
Wiertz, E. J., Tortorella, D., Bogyo, M., Yu, J., Mothes, W., Jones, T. R., 
Rapoport, T. A., & Ploegh, H. L. (1996). Sec61-mediated transfer of a 
membrane protein from the endoplasmic reticulum to the proteasome for 
destruction. Nature, 384(6608), 432–438. 
https://doi.org/10.1038/384432a0 
 
Wolters, J. C., Abele, R., & Tampé, R. (2005). Selective and ATP-dependent 
translocation of peptides by the homodimeric ATP binding cassette 
transporter TAP-like (ABCB9). The Journal of Biological Chemistry, 
280(25), 23631–23636. https://doi.org/10.1074/jbc.M503231200 
 
World Health Organization. (2019). World malaria report 2019. 
https://www.who.int/publications-detail/world-malaria-report-2019 
 
Xu, D.-M., Kong, Y.-L., Wang, L., Zhu, H.-Y., Wu, J.-Z., Xia, Y., Li, Y., Qin, S.-C., 
Fan, L., Li, J.-Y., Liang, J.-H., & Xu, W. (2019). EBV-miR-BHRF1-1 
Targets p53 Gene: Potential Role in Epstein-Barr Virus Associated 
Chronic Lymphocytic Leukemia. Cancer Research and Treatment: Official 
Journal of Korean Cancer Association. 
https://doi.org/10.4143/crt.2019.457 
 
Yang, Z., & Bjorkman, P. J. (2008). Structure of UL18, a peptide-binding viral 
MHC mimic, bound to a host inhibitory receptor. Proceedings of the 
National Academy of Sciences of the United States of America, 105(29), 
10095–10100. https://doi.org/10.1073/pnas.0804551105 
 
Yasuhara, A., Yamayoshi, S., Kiso, M., Sakai-Tagawa, Y., Koga, M., Adachi, E., 
Kikuchi, T., Wang, I.-H., Yamada, S., & Kawaoka, Y. (2019). Antigenic drift 
originating from changes to the lateral surface of the neuraminidase head 






Zhen, A., Peterson, C. W., Carrillo, M. A., Reddy, S. S., Youn, C. S., Lam, B. B., 
Chang, N. Y., Martin, H. A., Rick, J. W., Kim, J., Neel, N. C., Rezek, V. K., 
Kamata, M., Chen, I. S. Y., Zack, J. A., Kiem, H.-P., & Kitchen, S. G. 
(2017). Long-term persistence and function of hematopoietic stem cell-
derived chimeric antigen receptor T cells in a nonhuman primate model of 
HIV/AIDS. PLoS Pathogens, 13(12), e1006753. 
https://doi.org/10.1371/journal.ppat.1006753 
 
Zhou, X., Glas, R., Momburg, F., Hämmerling, G. J., Jondal, M., & Ljunggren, H. 
G. (1993). TAP2-defective RMA-S cells present Sendai virus antigen to 
cytotoxic T lymphocytes. European Journal of Immunology, 23(8), 1796–
1801. https://doi.org/10.1002/eji.1830230810 
 
Zwaveling, S., Mota, S. C. F., Nouta, J., Johnson, M., Lipford, G. B., Offringa, R., 
Burg, S. H. van der, & Melief, C. J. M. (2002). Established Human 
Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated 
Following Vaccination with Long Peptides. The Journal of Immunology, 





                                              
                   
